Universal Health Services (UHS) 10-Q 8 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Jul. 31, 2022
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Jun. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Trading Symbol	UHS
Entity Registrant Name	UNIVERSAL HEALTH SERVICES, INC.
Entity Central Index Key	0000352915
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	1-10765
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	23-2077891
Entity Address, Address Line One	UNIVERSAL CORPORATE CENTER
Entity Address, Address Line Two	367 SOUTH GULPH ROAD
Entity Address, City or Town	KING OF PRUSSIA
Entity Address, State or Province	PA
Entity Address, Postal Zip Code	19406
City Area Code	610
Local Phone Number	768-3300
Entity Interactive Data Current	Yes
Security Exchange Name	NYSE
Title of 12(b) Security	Class B Common Stock, $0.01 par value
Document Quarterly Report	true
Document Transition Report	false
Class A
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		6,577,100
Class B
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		65,717,179
Class C
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		661,688
Class D
Document Information [Line Items]
Entity Common Stock, Shares Outstanding		14,285

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Statement [Abstract]
Net revenues	$ 3,323,407	$ 3,197,880	$ 6,616,363	$ 6,210,867
Operating charges:
Salaries, wages and benefits	1,691,472	1,487,935	3,383,742	2,985,708
Other operating expenses	867,885	769,810	1,688,819	1,479,518
Supplies expense	354,993	338,033	726,066	685,143
Depreciation and amortization	143,850	133,985	287,634	265,388
Lease and rental expense	31,773	29,149	63,811	60,473
Operating Expenses, Total	3,089,973	2,758,912	6,150,072	5,476,230
Income from operations	233,434	438,968	466,291	734,637
Interest expense, net	25,676	21,299	47,349	43,256
Other (income) expense, net	(1,972)	(9,129)	9,229	(8,294)
Income before income taxes	209,730	426,798	409,713	699,675
Provision for income taxes	50,949	101,522	99,911	165,329
Net income	158,781	325,276	309,802	534,346
Less: Net income (loss) attributable to noncontrolling interests	(5,281)	252	(8,173)	231
Net income attributable to UHS	$ 164,062	$ 325,024	$ 317,975	$ 534,115
Basic earnings per share attributable to UHS	$ 2.22	$ 3.85	$ 4.27	$ 6.31
Diluted earnings per share attributable to UHS	$ 2.20	$ 3.79	$ 4.22	$ 6.22
Weighted average number of common shares - basic	73,682	84,224	74,356	84,503
Add: Other share equivalents	753	1,400	882	1,207
Weighted average number of common shares and equivalents - diluted	74,435	85,624	75,238	85,710

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 158,781	$ 325,276	$ 309,802	$ 534,346
Other comprehensive income (loss):
Foreign currency translation adjustment	(28,232)	(3,717)	(46,702)	(14,063)
Other comprehensive income (loss) before tax	(28,232)	(3,717)	(46,702)	(14,063)
Income tax expense (benefit) related to items of other comprehensive income (loss)	68	(601)	(876)	(2,067)
Total other comprehensive income (loss), net of tax	(28,300)	(3,116)	(45,826)	(11,996)
Comprehensive income	130,481	322,160	263,976	522,350
Less: Comprehensive income (loss) attributable to noncontrolling interests	(5,281)	252	(8,173)	231
Comprehensive income attributable to UHS	$ 135,762	$ 321,908	$ 272,149	$ 522,119

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 132,658	$ 115,301
Accounts receivable, net	1,835,238	1,746,635
Supplies	209,569	206,839
Other current assets	258,760	194,781
Total current assets	2,436,225	2,263,556
Property and equipment	11,057,885	10,770,702
Less: accumulated depreciation	(5,087,166)	(4,896,427)
Property, plant and equipment, net, Total	5,970,719	5,874,275
Other assets:
Goodwill	3,912,382	3,962,624
Deferred income taxes	51,548	45,707
Right of use assets-operating leases	360,791	367,477
Deferred charges	6,188	6,525
Other	558,250	573,379
Total Assets	13,296,103	13,093,543
Current liabilities:
Current maturities of long-term debt	66,205	48,409
Accounts payable and other liabilities	1,861,467	1,860,496
Operating lease liabilities	63,630	64,484
Federal and state taxes	396	10,720
Total current liabilities	1,991,698	1,984,109
Other noncurrent liabilities	496,639	464,759
Operating lease liabilities noncurrent	300,197	304,624
Long-term debt	4,599,204	4,141,879
Redeemable noncontrolling interests	4,449	5,119
Equity:
UHS common stockholders’ equity	5,814,660	6,089,664
Noncontrolling interest	89,256	103,389
Total equity	5,903,916	6,193,053
Total Liabilities and Stockholders’ Equity	$ 13,296,103	$ 13,093,543

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Equity - USD ($) $ in Thousands	Total	Redeemable Noncontrolling Interest	Common Stock Class A	Common Stock Class B	Common Stock Class C	Common Stock Class D	Cumulative Dividends	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	UHS Common Stockholders' Equity	Noncontrolling Interest
Balance at Dec. 31, 2020	$ 6,401,967		$ 66	$ 778	$ 7	$ 0	$ (479,503)	$ 6,747,678	$ 48,120	$ 6,317,146	$ 84,821
Balance at Dec. 31, 2020		$ 4,569
Common Stock
Issued/(converted)	6,444			5				6,439		6,444
Repurchased	(368,080)			(23)				(368,057)		(368,080)
Restricted share-based compensation expense	6,102							6,102		6,102
Dividends paid and accrued	(33,874)						(33,874)			(33,874)
Stock option expense	30,243							30,243		30,243
Distributions to noncontrolling interests	(5,414)	(203)									(5,414)
Purchase (sale) of ownership interests by (from) minority members	12,669										12,669
Comprehensive income:
Net income to UHS / noncontrolling interests	534,019	327						534,115		534,115	(96)
Foreign currency translation adjustments, net of income tax	(11,996)								(11,996)	(11,996)
Subtotal - comprehensive income	522,023							534,115	(11,996)	522,119	(96)
Subtotal attributable to redeemable noncontrolling interest		327
Balance at Jun. 30, 2021	6,572,080		66	760	7	0	(513,377)	6,956,520	36,124	6,480,100	91,980
Balance at Jun. 30, 2021		4,693
Balance at Mar. 31, 2021	6,601,839		66	781	7	0	(496,521)	6,970,289	39,240	6,513,862	87,977
Balance at Mar. 31, 2021		4,470
Common Stock
Issued/(converted)	3,084			1				3,083		3,084
Repurchased	(360,616)			(22)				(360,594)		(360,616)
Restricted share-based compensation expense	3,240							3,240		3,240
Dividends paid and accrued	(16,856)						(16,856)			(16,856)
Stock option expense	15,478							15,478		15,478
Distributions to noncontrolling interests	(889)	(203)									(889)
Purchase (sale) of ownership interests by (from) minority members	5,066										5,066
Comprehensive income:
Net income to UHS / noncontrolling interests	324,850	426						325,024		325,024	(174)
Foreign currency translation adjustments, net of income tax	(3,116)								(3,116)	(3,116)
Subtotal - comprehensive income	321,734							325,024	(3,116)	321,908	(174)
Subtotal attributable to redeemable noncontrolling interest		426
Balance at Jun. 30, 2021	6,572,080		66	760	7	0	(513,377)	6,956,520	36,124	6,480,100	91,980
Balance at Jun. 30, 2021		4,693
Balance at Dec. 31, 2021	6,193,053		66	698	7	0	(545,487)	6,604,089	30,291	6,089,664	103,389
Balance at Dec. 31, 2021		5,119
Common Stock
Issued/(converted)	6,795			6				6,789		6,795
Repurchased	(565,182)			(44)				(565,138)		(565,182)
Restricted share-based compensation expense	8,103							8,103		8,103
Dividends paid and accrued	(29,711)						(29,711)			(29,711)
Stock option expense	32,842							32,842		32,842
Distributions to noncontrolling interests	(4,673)	(650)									(4,673)
Purchase (sale) of ownership interests by (from) minority members	(1,307)										(1,307)
Comprehensive income:
Net income to UHS / noncontrolling interests	309,822	(20)						317,975		317,975	(8,153)
Foreign currency translation adjustments, net of income tax	(45,826)								(45,826)	(45,826)
Subtotal - comprehensive income	263,996							317,975	(45,826)	272,149	(8,153)
Subtotal attributable to redeemable noncontrolling interest		(20)
Balance at Jun. 30, 2022	5,903,916		66	660	7	0	(575,198)	6,404,660	(15,535)	5,814,660	89,256
Balance at Jun. 30, 2022	4,000	4,449
Balance at Mar. 31, 2022	5,962,578		66	676	7	0	(560,450)	6,414,808	12,765	5,867,872	94,706
Balance at Mar. 31, 2022		4,314
Common Stock
Issued/(converted)	3,150			1				3,149		3,150
Repurchased	(199,677)			(17)				(199,660)		(199,677)
Restricted share-based compensation expense	4,661							4,661		4,661
Dividends paid and accrued	(14,748)						(14,748)			(14,748)
Stock option expense	17,640							17,640		17,640
Distributions to noncontrolling interests	(34)										(34)
Comprehensive income:
Net income to UHS / noncontrolling interests	158,646	135						164,062		164,062	(5,416)
Foreign currency translation adjustments, net of income tax	(28,300)								(28,300)	(28,300)
Subtotal - comprehensive income	130,346							164,062	(28,300)	135,762	(5,416)
Subtotal attributable to redeemable noncontrolling interest		135
Balance at Jun. 30, 2022	5,903,916		$ 66	$ 660	$ 7	$ 0	$ (575,198)	$ 6,404,660	$ (15,535)	$ 5,814,660	$ 89,256
Balance at Jun. 30, 2022	$ 4,000	$ 4,449

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash Flows from Operating Activities:
Net income	$ 309,802	$ 534,346
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation & amortization	287,634	265,388
(Gain) loss on sale of assets and businesses	1,084	(4,803)
Stock-based compensation expense	41,640	37,031
Provision for asset impairment		7,195
Changes in assets & liabilities, net of effects from acquisitions and dispositions:
Accounts receivable	(89,729)	(35,903)
Accrued interest	1,329	(1,459)
Accrued and deferred income taxes	(34,260)	(26,769)
Other working capital accounts	(98,811)	3,560
Medicare accelerated payments and deferred CARES Act and other grants	5,339	(697,011)
Other assets and deferred charges	30,278	(28,763)
Other	(15,763)	5,052
Accrued insurance expense, net of commercial premiums paid	97,570	104,079
Payments made in settlement of self-insurance claims	(58,066)	(42,495)
Net cash provided by operating activities	478,047	119,448
Cash Flows from Investing Activities:
Property and equipment additions	(407,962)	(482,211)
Proceeds received from sales of assets and businesses	10,232	21,143
Acquisition of businesses and property	(12,485)
Inflows (outflows) from foreign exchange contracts that hedge our net U.K. investment	84,535	(21,487)
Decrease in capital reserves of commercial insurance subsidiary	100	100
Costs incurred for purchase of information technology applications, net of refunds		(1,246)
Net cash used in investing activities	(325,580)	(483,701)
Cash Flows from Financing Activities:
Repayments of long-term debt	(226,854)	(278,785)
Additional borrowings, net	700,000	6,578
Financing costs	(2,387)
Repurchase of common shares	(565,182)	(368,080)
Dividends paid	(29,641)	(33,844)
Issuance of common stock	6,661	6,442
Profit distributions to noncontrolling interests	(5,323)	(5,617)
Purchase (sale) of ownership interests by (from) minority members	(1,307)	11,433
Net cash used in financing activities	(124,033)	(661,873)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(5,457)	660
Increase (decrease) in cash, cash equivalents and restricted cash	22,977	(1,025,466)
Cash, cash equivalents and restricted cash, beginning of period	178,934	1,279,154
Cash, cash equivalents and restricted cash, end of period	201,911	253,688
Supplemental Disclosures of Cash Flow Information:
Interest paid	43,796	43,641
Income taxes paid, net of refunds	145,448	189,979
Noncash purchases of property and equipment	$ 112,420	$ 95,979

General

General	6 Months Ended
	Jun. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
General	(1) General This Quarterly Report on Form 10-Q is for the quarterly period ended June 30, 2022. In this Quarterly Report, “we,” “us,” “our” “UHS” and the “Company” refer to Universal Health Services, Inc. and its subsidiaries. The condensed consolidated interim financial statements include the accounts of our majority-owned subsidiaries and partnerships and limited liability companies controlled by us, or our subsidiaries, as managing general partner or managing member. The condensed consolidated interim financial statements included herein have been prepared by us, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and reflect all adjustments (consisting only of normal recurring adjustments) which, in our opinion, are necessary to fairly state results for the interim periods. Certain information and footnote disclosures normally included in audited consolidated financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations, although we believe that the accompanying disclosures are adequate to make the information presented not misleading. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements, significant accounting policies and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2021. The impact of the COVID-19 pandemic, which began during the second half of March, 2020, has had a material effect on our operations and financial results since that time. The length and extent of the disruptions caused by the COVID‑19 pandemic are currently unknown. We believe that the adverse impact that COVID-19 will have on our future operations and financial results will depend upon many factors, most of which are beyond our capability to control or predict. Our future operations and financial results may be materially impacted by developments related to COVID-19 including, but not limited to, the potential impact on future COVID-19 patient volumes resulting from new variants of the virus, the length of time and severity of the spread of the pandemic; the volume of cancelled or rescheduled elective procedures and the volume of COVID-19 patients treated at our hospitals and other healthcare facilities; measures we are taking to respond to the COVID-19 pandemic; the impact of government and administrative regulation and stimulus on the hospital industry and potential retrospective adjustment in future periods of CARES Act and other grant income revenues recorded as revenues in prior periods; the requirements that federal healthcare program participation is conditional upon facility employees being vaccinated; declining patient volumes and unfavorable changes in payer mix caused by deteriorating macroeconomic conditions (including increases in uninsured and underinsured patients as the result of business closings The nationwide shortage of nurses and other clinical staff and support personnel has been a significant operating issue facing us and other healthcare providers. Like others in the healthcare industry, we continue to experience a shortage of nurses and other clinical staff and support personnel at our acute care and behavioral health care hospitals in many geographic areas. In some areas, the labor scarcity is putting a strain on our resources and staff, which has required us to utilize higher‑cost temporary labor and pay premiums above standard compensation for essential workers. This staffing shortage has required us to hire expensive temporary personnel and/or enhance wages and benefits to recruit and retain nurses and other clinical staff and support personnel. At certain facilities, particularly within our behavioral health care segment, we have been unable to fill all vacant positions and, consequently, have been required to limit patient volumes. These factors had a material unfavorable impact on our results of operations during the first six months of 2022. During 2021, we received approximately $189 million of additional funds from the federal government in connection with the CARES Act, substantially all of which was received during the first quarter of 2021. During the second quarter of 2021, we returned the $189 million to the appropriate government agencies utilizing a portion of our cash and cash equivalents held on deposit. T Also, in March of 2021, we made an early repayment of $695 million of funds received during 2020 pursuant to the Medicare Accelerated and Advance Payment Program. These funds were returned to the government utilizing a portion of our cash and cash equivalents held on deposit.

Relationship with Universal Hea

Relationship with Universal Health Realty Income Trust and Other Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Relationship with Universal Health Realty Income Trust and Other Related Party Transactions	(2) Relationship with Universal Health Realty Income Trust and Other Related Party Transactions Relationship with Universal Health Realty Income Trust: At June 30, 2022, we held approximately 5.7% of the outstanding shares of Universal Health Realty Income Trust (the “Trust”). We serve as Advisor to the Trust under an annually renewable advisory agreement, which is scheduled to expire on December 31 st In addition, certain of our officers and directors are also officers and/or directors of the Trust. Management believes that it has the ability to exercise significant influence over the Trust, therefore we account for our investment in the Trust using the equity method of accounting. Our pre-tax share of income from the Trust, which is included in other income, net, on the accompanying consolidated statements of income for each period was approximately $307,000 and $394,000 during the three-month periods ended June 30, 2022 and 2021, respectively, and approximately $607,000 and $701,000 during the six-month periods ended June 30, 2022 and 2021, respectively. Included in our share of the Trust’s income for the three and six-month periods ended June 30, 2021 was a gain realized by the Trust in connection with a divestiture of property that was completed during the second quarter of 2021. We received dividends from the Trust amounting to $559,000 and $551,000 during the three-month periods ended June 30, 2022 and 2021, respectively, and $1.1 million during each of the six-month periods ended June 30, 2022 and 2021. The carrying value of our investment in the Trust was approximately $8.9 million and $9.4 million at June 30, 2022 and December 31, 2021, respectively, and is included in other assets in the accompanying consolidated balance sheets. The market value of our investment in the Trust was $41.9 million at June 30, 2022 and $46.8 million at December 31, 2021, based on the closing price of the Trust’s stock on the respective dates. The Trust commenced operations in 1986 by purchasing certain properties from us and immediately leasing the properties back to our respective subsidiaries. The base rents are paid monthly and the bonus rents, which as of January 1, 2022 are applicable to only McAllen Medical Center, are computed and paid on a quarterly basis, based upon a computation that compares current quarter revenue to a corresponding quarter in the base year. The leases with those subsidiaries are unconditionally guaranteed by us and are cross-defaulted with one another. On December 31, 2021, we entered into an asset purchase and sale agreement with the Trust. Pursuant to the terms of the asset purchase and sale agreement, which was amended during the first quarter of 2022, a wholly-owned subsidiary of ours purchased from the Trust the real estate assets of the Inland Valley Campus of Southwest Healthcare System (at its fair market value of $79.6 million). Additionally, two wholly-owned subsidiaries of ours transferred to the Trust the real estate assets of Aiken Regional Medical Center (at its fair market value of $57.7 million) and Canyon Creek Behavioral Health (at its fair market value of $26.0 million). In connection with this transaction, since the $83.7 million aggregate fair market value of Aiken Regional Medical Center (“Aiken”) and Canyon Creek Behavioral Health (“Canyon Creek”) exceeded the $79.6 million fair market value of the Inland Valley Campus of Southwest Healthcare System, we received approximately $4.1 million in cash from the Trust. Pursuant to the leases, as amended, the aggregate annual rental during 2022 for Aiken and Canyon Creek aggregates to approximately $5.7 million ($3.9 million related to Aiken and $1.8 million related to Canyon Creek). There is no bonus rental component applicable to the leases for these two facilities. The asset purchase and sale transaction was accounted for as a financing arrangement and, since we did not derecognize the real property related to Aiken and Canyon Creek, we will continue to depreciate the assets. Our consolidated balance sheet as of June 30, 2022 reflects a financial liability of $82.5 million, which is included in debt, related to this transaction. Our monthly lease payments payable to the Trust will be recorded to interest expense and as a reduction to the outstanding financial liability. The aggregate rental for the leases on the four wholly-owned hospital facilities with the Trust was approximately $5 million and $10 million during the three and six months ended June 30, 2022, respectively. The aggregate rental for the leases on the three wholly-owned hospital facilities with the Trust was approximately $4 million and $8 million during the three and six months ended June 30, 2021, respectively. Pursuant to the Master Leases by certain subsidiaries of ours and the Trust as described in the table below, dated 1986 and 2021 (“the Master Leases”) which govern the leases of McAllen Medical Center and Wellington Regional Medical Center (each of which is governed by the Master Lease dated 1986), and Aiken Regional Medical Center and Canyon Creek Behavioral Health (each of which is governed by the Master Lease dated 2021), we have the option to renew the leases at the lease terms described above and below by providing notice to the Trust at least 90 days prior to the termination of the then current term. We also have the right to purchase the respective leased hospitals at their appraised fair market value upon any of the following: (i) at the end of the lease terms or any renewal terms; (ii) upon one month’s notice should a change of control of the Trust occur, or; (iii) within the time period as specified in the lease in the event that we provide notice to the Trust of our intent to offer a substitution property/properties in exchange for one (or more) of the hospital properties leased from the Trust should we be unable to reach an agreement with the Trust on the properties to be substituted. In addition, we have rights of first refusal to: (i) purchase the respective leased facilities during and for 180 days after the lease terms at the same price, terms and conditions of any third-party offer, or; (ii) renew the lease on the respective leased facility at the end of, and for 180 days after, the lease term at the same terms and conditions pursuant to any third-party offer. In addition, we are the managing, majority member in a joint venture with an unrelated third-party that operates Clive Behavioral Health, a 100-bed behavioral health care facility located in Clive, Iowa. The real property of this newly constructed facility, which was completed and opened in late 2020, is also leased from the Trust pursuant to the lease terms as provided in the table below. The rental on this facility was approximately $657,000 and $622,000 for the three months ended June 30, 2022 and 2021, respectively, and approximately $1.3 million and $1.2 million for the six months ended June 30, 2022 and 2021, respectively. In connection with the lease on this facility, the joint venture has the right to purchase the leased facility from the Trust at its appraised fair market value upon either of the following: (i) by providing notice at least 270 days prior to the end of the lease terms or any renewal terms, or; (ii) upon 30 days’ notice anytime within 12 months of a change of control of the Trust. Additionally, the joint venture has rights of first offer to purchase the facility prior to any third-party sale. The table below provides certain details for each of the hospitals leased from the Trust as of June 30, 2022: Hospital Name Annual Minimum Rent End of Lease Term Renewal Term (years) McAllen Medical Center $ 5,485,000 December, 5 (a) Wellington Regional Medical Center $ 6,319,000 December, 5 (b) Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services $ 3,895,000 December, 35 (c) Canyon Creek Behavioral Health $ 1,670,000 December, 35 (c) Clive Behavioral Health Hospital $ 2,628,000 December, 50 (d) (a) We have one 5-year renewal option at existing lease rates (through 2031). (b) We have one 5-year renewal options at fair market value lease rates (through 2031). Upon the December 31, 2021 expiration of the lease on Wellington Regional Medical Center, a wholly-owned subsidiary of ours exercised its fair market value renewal option and renewed the lease for a 5-year term scheduled to expire on December 31, 2026. Effective January 1, 2022, the annual fair market value lease rate for this hospital is $6.3 million (there is no longer a bonus rental component of the lease payment). Beginning on January 1, 2023, and thereafter on each January 1 st (c) We have seven 5-year (d) This facility is operated by a joint venture in which we are the managing, majority member and an unrelated third-party holds a minority ownership interest. The joint venture has three, 10-year renewal options at computed lease rates as stipulated in the lease (2041 through 2070) and two additional, 10-year renewal options at fair market values lease rates (2071 through 2090). Beginning in January, 2022, and thereafter in each January through 2040 (and potentially through 2070 if three, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis. In addition, certain of our subsidiaries are tenants in several medical office buildings (“MOBs”) and two free-standing emergency departments owned by the Trust or by limited liability companies in which the Trust holds 95% to 100% of the ownership interest. In January, 2022, the Trust commenced construction on a new 86,000 rentable square feet multi-tenant MOB that is located on the campus of Northern Nevada Sierra Medical Center in Reno, Nevada. Northern Nevada Sierra Medical Center, a 170-bed newly constructed acute care hospital owned and operated by a wholly-owned subsidiary of ours, was completed and opened in April, 2022. In connection with this MOB, a ground lease and a master flex lease was executed between a wholly-owned subsidiary of ours and the Trust, pursuant to the terms of which our subsidiary will master lease approximately 68% of the rentable square feet of the MOB at an initial minimum rent of $1.3 million annually. The master flex lease could be reduced during the term if certain conditions are met. Other Related Party Transactions: In December, 2010, our Board of Directors approved the Company’s entering into supplemental life insurance plans and agreements on the lives of Alan B. Miller (our Executive Chairman of the Board) and his wife. As a result of these agreements, as amended in October, 2016, based on actuarial tables and other assumptions, during the life expectancies of the insureds, we would pay approximately $28 million in premiums, and certain trusts owned by our Executive Chairman of the Board, would pay approximately $9 million in premiums. Based on the projected premiums mentioned above, and assuming the policies remain in effect until the death of the insureds, we will be entitled to receive death benefit proceeds of no less than approximately $37 million representing the $28 million of aggregate premiums paid by us as well as the $9 million of aggregate premiums paid by the trusts. In connection with these policies, we will pay/we paid approximately $ 1.0 million , net, in premium payments during each of the 20 2 2 and 20 2 1 years , respectively . In August, 2015, Marc D. Miller, our President and Chief Executive Officer and member of our Board of Directors, was appointed to the Board of Directors of Premier, Inc. (“Premier”), a healthcare performance improvement alliance. During 2013, we entered into a new group purchasing organization agreement (“GPO”) with Premier. In conjunction with the GPO agreement, we acquired a minority interest in Premier for a nominal amount. During the fourth quarter of 2013, in connection with the completion of an initial public offering of the stock of Premier, we received cash proceeds for the sale of a portion of our ownership interest in the GPO. Also in connection with this GPO agreement, we received shares of restricted stock of Premier which vested ratably over a seven-year Additionally, Premier declared and paid quarterly cash dividends during each of the first two quarters of 2022 and 2021. Our share of the cash dividends amounted to approximately $450,000 and $400,000 for the three-month periods ended June 30, 2022 and 2021, respectively, and approximately $900,000 and $800,000 for the six-month periods ended June 30, 2022 and 2021, respectively. The dividends are included in A member of our Board of Directors and member of the Executive Committee and Finance Committee is a partner in Norton Rose Fulbright US LLP, a law firm engaged by us for a variety of legal services. The Board member and his law firm also provide personal legal services to our Executive Chairman and he acts as trustee of certain trusts for the benefit of our Executive Chairman and his family.

Other Noncurrent liabilities an

Other Noncurrent liabilities and Redeemable/Noncontrolling Interests	6 Months Ended
	Jun. 30, 2022
Noncontrolling Interest [Abstract]
Other Noncurrent liabilities and Redeemable/Noncontrolling Interests	(3) Other Noncurrent liabilities and Redeemable/Noncontrolling Interests Other noncurrent liabilities include the long-term portion of our professional and general liability, workers’ compensation reserves, pension and deferred compensation liabilities, and liabilities incurred in connection with split-dollar life insurance agreements on the lives of our chief executive officer and his wife. As of June 30, 2022, outside owners held noncontrolling, minority ownership interests of: (i) 20% in an acute care facility located in Washington, D.C.; (ii) approximately 7% in an acute care facility located in Texas; (iii) 49%, 20%, 30%, 20%, 25%, 48% and 26% in seven behavioral health care facilities located in Arizona, Pennsylvania, Ohio, Washington, Missouri, Iowa and Michigan, respectively, and; (iv) approximately 5% in an acute care facility located in Nevada. The noncontrolling interest and redeemable noncontrolling interest balances of $89 million and $4 million, respectively, as of June 30, 2022, consist primarily of the third-party ownership interests in these hospitals. In connection with the two behavioral health care facilities located in Pennsylvania and Ohio, the minority ownership interests of which are reflected as redeemable noncontrolling interests on our Condensed Consolidated Balance Sheet, the outside owners have “put options” to put their entire ownership interest to us at any time. If exercised, the put option requires us to purchase the minority member’s interest at fair market value. Accordingly, the amounts recorded as redeemable noncontrolling interests on our Condensed Consolidated Balance Sheet reflects the estimated fair market value of these ownership interests.

Treasury

Treasury	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Treasury	(4) Treasury Credit Facilities and Outstanding Debt Securities: In June, 2022 we entered into a ninth amendment to our credit agreement dated as of November 15, 2010, as amended and restated as of September, 2012, August, 2014, October, 2018, August, 2021, and September, 2021, among UHS, as borrower, the several banks and other financial institutions from time to time parties thereto, as lenders, and JPMorgan Chase Bank, N.A., as administrative agent, (the “Credit Agreement”). The ninth amendment provided for, among other things, the following: (i) a new incremental tranche A term loan facility in the aggregate principal amount of $700 million which is scheduled to mature on August 24, 2026, and; (ii) replaces the option to make Eurodollar borrowings (which bear interest by reference to the LIBOR Rate) with Term Benchmark Loans, which will bear interest by reference to the Secured Overnight Financing Rate ( “SOFR”) In September, 2021 we entered into an eighth amendment to our Credit Agreement which modified the definition of “Adjusted LIBO Rate”. In August, 2021 we entered into a seventh amendment to our Credit Agreement which, among other things, provided for the following: o a $1.2 billion aggregate amount revolving credit facility, which is scheduled to mature on August 24, 2026, representing an increase of $200 million over the $1.0 billion previous commitment. As of June 30, 2022, this facility had $140 million of borrowings outstanding and $1.056 billion of available borrowing capacity, net of $4 million of outstanding letters of credit; o a $1.7 billion initial tranche A term loan facility which was subsequently increased by $700 million in June, 2022 by the above-mentioned ninth amendment. The seventh amendment also provided for repayment of $150 million of borrowings outstanding pursuant to the previous tranche A term loan facility, and; o repayment of approximately $488 million of outstanding borrowings and termination of the previous tranche B term loan facility. The terms of the tranche A term loan facility, as amended, which had $2.368 billion of outstanding borrowings as of June 30, 2022, provides for installment payments of $15.0 million per quarter during the period of September, 2022 through September, 2023, and $30.0 million per quarter during the period of December, 2023 through June, 2026. The unpaid principal balance at June 30, 2026 is payable on the August 24, 2026 scheduled maturity date of the Credit Agreement. Revolving credit and tranche A term loan borrowings under the Credit Agreement bear interest at our election at either (1) the ABR rate which is defined as the rate per annum equal to the greatest of (a) the lender’s prime rate, (b) the weighted average of the federal funds rate, plus 0.5% and (c) one month SOFR rate plus 1%, in each case, plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 0.25% to 0.625%, or (2) the one, three or six month SOFR rate plus 0.1% (at our election), plus an applicable margin based upon our consolidated leverage ratio at the end of each quarter ranging from 1.25% to 1.625%. As of June 30, 2022, the applicable margins were 0.375% for ABR-based loans and 1.375% for SOFR-based loans under the revolving credit and term loan A facilities. The revolving credit facility includes a $125 million sub-limit for letters of credit. The Credit Agreement is secured by certain assets of the Company and our material subsidiaries (which generally excludes asset classes such as substantially all of the patient-related accounts receivable of our acute care hospitals, and certain real estate assets and assets held in joint-ventures with third parties) and is guaranteed by our material subsidiaries. The Credit Agreement includes a material adverse change clause that must be represented at each draw. The Credit Agreement also contains covenants that include a limitation on sales of assets, mergers, change of ownership, liens, indebtedness, transactions with affiliates, dividends and stock repurchases; and requires compliance with financial covenants including maximum leverage. We were in compliance with all required covenants as of June 30, 2022 and December 31, 2021. On August 24, 2021, we completed the following via private offerings to qualified institutional buyers under Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended: o Issued $700 million of aggregate principal amount of 1.65% senior secured notes due on September 1, 2026, and; o Issued $500 million of aggregate principal amount of 2.65% senior secured notes due on January 15, 2032. In April, 2021 our accounts receivable securitization program (“Securitization”) was amended (the eighth amendment) to: (i) reduce the aggregate borrowing commitments to $20 million (from $450 million previously); (ii) slightly reduce the borrowing rates and commitment fee, and; (iii) extend the maturity date to April 25, 2022. In April, 2022, the Securitization was amended (the ninth amendment) to extend the maturity date to July 22, 2022. In July, 2022, the Securitization was amended (the tenth amendment) to extend the maturity date to September 20, 2022. Substantially all other material terms and conditions remained unchanged. There were no borrowings outstanding pursuant to the Securitization as of June 30, 2022. On September 13, 2021, we redeemed $400 million of aggregate principal amount of 5.00% senior secured notes, that were scheduled to mature on June 1, 2026, at 102.50% of the aggregate principal, or $410 million. As of June 30, 2022, we had combined aggregate principal of $2.0 billion from the following senior secured notes: o $700 million aggregate principal amount of 1.65% senior secured notes due in September, 2026 (“2026 Notes”) which were issued on August 24, 2021. o $800 million aggregate principal amount of 2.65% senior secured notes due in October, 2030 (“2030 Notes”) which were issued on September 21, 2020. o $500 million of aggregate principal amount of 2.65% senior secured notes due in January, 2032 (“2032 Notes”) which were issued on August 24, 2021. On September 28, 2020, we redeemed the entire $700 million aggregate principal amount of our previously outstanding 4.75% senior secured notes, which were scheduled to mature in August, 2022, at 100% of the aggregate principal amount. Interest on the 2026 Notes is payable on March 1st and September 1st until the maturity date of September 1, 2026. Interest on the 2030 Notes payable on April 15th and October 15th, until the maturity date of October 15, 2030. th th The 2026 Notes, 2030 Notes and 2032 Notes (collectively “The Notes”) were offered only to qualified institutional buyers under Rule 144A and to non-U.S. persons outside the United States in reliance on Regulation S under the Securities Act of 1933, as amended (the “Securities Act”). The Notes have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. The Notes are guaranteed (the “ Guarantees ”) on a senior secured basis by all of our existing and future direct and indirect subsidiaries (the “ Subsidiary Guarantors ”) that guarantee our Credit Agreement, or other first lien obligations or any junior lien obligations. The Notes and the Guarantees are secured by first-priority liens, subject to permitted liens, on certain of the Company’s and the Subsidiary Guarantors’ assets now owned or acquired in the future by the Company or the Subsidiary Guarantors (other than real property, accounts receivable sold pursuant to the Company’s Existing Receivables Facility (as defined in the Indenture pursuant to which The Notes were issued (the “Indenture”)), and certain other excluded assets). The Company’s obligations with respect to The Notes, the obligations of the Subsidiary Guarantors under the Guarantees, and the performance of all of the Company’s and the Subsidiary Guarantors’ other obligations under the Indenture, are secured equally and ratably with the Company’s and the Subsidiary Guarantors’ obligations under the Credit Agreement and The Notes by a perfected first-priority security interest, subject to permitted liens, in the collateral owned by the Company and its Subsidiary Guarantors, whether now owned or hereafter acquired. However, the liens on the collateral securing The Notes and the Guarantees will be released if: (i) The Notes have investment grade ratings; (ii) no default has occurred and is continuing, and; (iii) the liens on the collateral securing all first lien obligations (including the Credit Agreement and The Notes) and any junior lien obligations are released or the collateral under the Credit Agreement, any other first lien obligations and any junior lien obligations is released or no longer required to be pledged. The liens on any collateral securing The Notes and the Guarantees will also be released if the liens on that collateral securing the Credit Agreement, other first lien obligations and any junior lien obligations are released. In connection with the issuance of The Notes, the Company, the Subsidiary Guarantors and the representatives of the several initial purchasers, entered into Registration Rights Agreements (the “ Registration Rights Agreements ”), whereby the Company and the Subsidiary Guarantors have agreed, at their expense, to use commercially reasonable best efforts to: (i) cause to be filed a registration statement enabling the holders to exchange The Notes and the Guarantees for registered senior secured notes issued by the Company and guaranteed by the then Subsidiary Guarantors under the Indenture (the “ Exchange Securities ”), containing terms identical to those of The Notes (except that the Exchange Securities will not be subject to restrictions on transfer or to any increase in annual interest rate for failure to comply with the Registration Rights Agreements); (ii) cause the registration statement to become effective; (iii) complete the exchange offer not later than 60 days after such effective date and in any event on or prior to a target registration date of March 21, 2023 in the case of the 2030 Notes and February 24, 2024 in the case of the 2026 and 2032 Notes, and; (iv) file a shelf registration statement for the resale of The Notes if the exchange offers cannot be effected within the time periods listed above. The interest rate on The Notes will increase and additional interest thereon will be payable if the Company does not comply with its obligations under the Registration Rights Agreements. As discussed in Note 2 As a result of our purchase option within the Aiken and Canyon Creek lease agreements, this asset purchase and sale transaction is accounted for as a failed sale leaseback in accordance with U.S. GAAP and we have accounted for the transaction as a financing arrangement. Our lease payments payable to the Trust are recorded to interest expense and as a reduction of the outstanding financial liability, and the amount allocated to interest expense is determined based upon our incremental borrowing rate and the outstanding financial liability. In connection with this transaction, our Consolidated Balance Sheets at June 30, 2022 and December 31, 2021 reflect financial liabilities, which are included in debt, of approximately $82 million as of each date. At June 30, 2022, the carrying value and fair value of our debt were approximately $4.7 billion and $4.3 billion, respectively. At December 31, 2021, the carrying value and fair value of our debt were each approximately $4.2 billion. The fair value of our debt was computed based upon quotes received from financial institutions. We consider these to be “level 2” in the fair value hierarchy as outlined in the authoritative guidance for disclosures in connection with debt instruments. Cash Flow Hedges: During the six-month period ended June 30, 2022 and the year ended December 31, 2021, we had no cash flow hedges outstanding. Foreign Currency Forward Exchange Contracts: We use forward exchange contracts to hedge our net investment in foreign operations against movements in exchange rates. The effective portion of the unrealized gains or losses on these contracts is recorded in foreign currency translation adjustment within accumulated other comprehensive income and remains there until either the sale or liquidation of the subsidiary. In connection with these forward exchange contracts, we recorded net cash inflows of $85 million during the six-month period ended June 30, 2022 and net cash outflows of $21 million during the six-month period ended June 30, 2021. Derivatives Hedging Relationships: The following table presents the effects of our foreign currency foreign exchange contracts on our results of operations for the three and six-month periods ended June 30, 2022 and 2021 (in thousands): Gain/(Loss) recognized in AOCI Three months ended Six months ended June 30, June 30, June 30, June 30, 2022 2021 2022 2021 Net Investment Hedge relationships Foreign currency foreign exchange contracts $ 64,464 $ (9,917 ) $ 81,576 $ (31,031 ) No other gains or losses were recognized in income related to derivatives in Subtopic 815-20. Cash, Cash Equivalents and Restricted Cash: Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follows (in thousands): June 30, June 30, December 31, 2022 2021 2021 Cash and cash equivalents $ 132,658 $ 199,017 $ 115,301 Restricted cash (a) 69,253 54,671 63,633 Total cash, cash equivalents and restricted cash $ 201,911 $ 253,688 $ 178,934 (a) Restricted cash is included in other assets on the accompanying consolidated balance sheet.

Fair Value Measurement

Fair Value Measurement	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurement	(5) Fair Value Measurement Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The following fair value hierarchy classifies the inputs to valuation techniques used to measure fair value into one of three levels: • Level 1: Unadjusted quoted prices in active markets for identical assets or liabilities. • Level 2: Inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly. These included quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active. • Level 3: Unobservable inputs that reflect the reporting entity’s own assumptions. The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Balance Sheet Basis of Fair Value Measurement (in thousands) June 30, 2022 Location Level 1 Level 2 Level 3 Assets: Money market mutual funds 85,037 Other assets 85,037 Certificates of deposit 2,200 Other assets 2,200 Equity securities 79,662 Other assets 79,662 Deferred compensation assets 38,690 Other assets 38,690 Foreign currency exchange contracts 1,602 Other current assets 1,602 $ 207,191 $ 203,389 $ 3,802 - Liabilities: Deferred compensation liability 38,690 Other noncurrent liabilities 38,690 $ 38,690 $ 38,690 - - Balance at Balance Sheet Basis of Fair Value Measurement (in thousands) December 31, 2021 Location Level 1 Level 2 Level 3 Assets: Money market mutual funds 79,900 Other assets 79,900 Certificates of deposit 2,300 Other assets 2,300 Equity securities 91,919 Other assets 91,919 Deferred compensation assets 45,759 Other assets 45,759 Foreign currency exchange contracts 1,357 Other current assets 1,357 $ 221,235 $ 217,578 $ 3,657 - Liabilities: Deferred compensation liability 45,759 Other noncurrent liabilities $ 45,759 $ 45,759 $ 45,759 - - The fair value of our money market mutual funds, certificates of deposit and equity securities with a readily determinable fair value are computed based upon quoted market prices in an active market. The fair value of deferred compensation assets and offsetting liability are computed based on market prices in an active market held in a rabbi trust. The fair value of our interest rate swaps are based on quotes from our counter parties. The fair value of our foreign currency exchange contracts is valued using quoted forward exchange rates and spot rates at the reporting date.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	(6) Commitments and Contingencies Professional and General Liability, Workers’ Compensation Liability The vast majority of our subsidiaries are self-insured for professional and general liability exposure up to: (i) $20 million for professional liability and $3 million for general liability per occurrence in 2022 and 2021; (ii) $10 million and $3 million per occurrence in 2020 (professional liability claims are also subject to an additional annual aggregate self-insured retention of $2.5 million for claims in excess of $10 million for 2020); (iii) $5 million and $3 million per occurrence, respectively, during 2019, 2018 and 2017, and; (iv) $10 million and $3 million per occurrence, respectively, prior to 2017. These subsidiaries are provided with several excess policies through commercial insurance carriers which provide for coverage in excess of the applicable per occurrence and aggregate self-insured retention or underlying policy limits 2014 through 2020. As of June 30, 2022, the total net accrual for our professional and general liability claims was $382 million, of which $74 million was included in current liabilities. As of December 31, 2021, the total net accrual for our professional and general liability claims was $349 million, of which $74 million was included in current liabilities. As a result of unfavorable trends experienced during 2022 and 2021, our results of operations included pre-tax increases to our reserves for self-insured professional and general liability claims amounting to approximately $16 million during the three and six-month periods ended June 30, 2022 and $36 million during the three and six-month periods ended June 30, 2021. Our estimated liability for self-insured professional and general liability claims is based on a number of factors including, among other things, the number of asserted claims and reported incidents, estimates of losses for these claims based on recent and historical settlement amounts, estimates of incurred but not reported claims based on historical experience, and estimates of amounts recoverable under our commercial insurance policies. While we continuously monitor these factors, our ultimate liability for professional and general liability claims could change materially from our current estimates due to inherent uncertainties involved in making this estimate. Given our significant self-insured exposure for professional and general liability claims, there can be no assurance that a sharp increase in the number and/or severity of claims asserted against us will not have a material adverse effect on our future results of operations. As of June 3 0 , 2022, the total accrual for our workers’ compensation liability claims was $ million, $ 55 million of which was included in current liabilities. As of December 31, 2021, the total accrual for our workers’ compensation liability claims was $ 115 million, $ 55 million of which was included in current liabilities. Although we are unable to predict whether or not our future financial statements will require updates to estimates for our prior year reserves for self-insured general and professional and workers’ compensation claims, given the relatively unpredictable nature of these potential liabilities and the factors impacting these reserves, as discussed above, it is reasonably likely that our future financial results may include material adjustments to prior period reserves. Property Insurance We have commercial property insurance policies for our properties covering catastrophic losses, including windstorm damage, up to a $1 billion policy limit, subject to a per occurrence/per location deductible of $2.5 million as of June 1, 2020. Losses resulting from named windstorms are subject to deductibles between 3% and 5% of the total insurable value of the property. In addition, we have commercial property insurance policies covering catastrophic losses resulting from earthquake and flood damage, each subject to aggregated loss limits (as opposed to per occurrence losses). Commercially insured earthquake coverage for our facilities is subject to various deductibles and limitations including: (i) $150 million limitation for our facilities located in California; (ii) $100 million limitation for our facilities located in fault zones within the United States; (iii) $40 million limitation for our facilities located in Puerto Rico, and; (iv) $250 million limitation for many of our facilities located in other states. Our commercially insured flood coverage has a limit of $100 million annually. There is also a $10 million sublimit for one of our facilities located in Houston, Texas, and a $1 million sublimit for our facilities located in Puerto Rico. Property insurance for our behavioral health facilities located in the U.K. are provided on an all risk basis up to a £1.5 billion policy limit, with coverage caps per location, that includes coverage for real and personal property as well as business interruption losses. Although we are unable to predict whether or not our future financial statements will require updates to estimates for our reserves for self-insured general and professional and workers’ compensation claims, given the relatively unpredictable nature of these potential liabilities and the factors impacting these reserves, as discussed above, it is reasonably likely that our future financial results may include material adjustments to prior period reserves. Legal Proceedings We operate in a highly regulated and litigious industry which subjects us to various claims and lawsuits in the ordinary course of business as well as regulatory proceedings and government investigations. These claims or suits include claims for damages for personal injuries, medical malpractice, commercial/contractual disputes, wrongful restriction of, or interference with, physicians’ staff privileges, and employment related claims. In addition, health care companies are subject to investigations and/or actions by various state and federal governmental agencies or those bringing claims on their behalf. Government action has increased with respect to investigations and/or allegations against healthcare providers concerning possible violations of fraud and abuse and false claims statutes as well as compliance with clinical and operational regulations. Currently, and from time to time, we and some of our facilities are subjected to inquiries in the form of subpoenas, Civil Investigative Demands, audits and other document requests from various federal and state agencies. These inquiries can lead to notices and/or actions including repayment obligations from state and federal government agencies associated with potential non-compliance with laws and regulations. Further, the federal False Claims Act allows private individuals to bring lawsuits (qui tam actions) against healthcare providers that submit claims for payments to the government. Various states have also adopted similar statutes. When such a claim is filed, the government will investigate the matter and decide if they are going to intervene in the pending case. These qui tam lawsuits are placed under seal by the court to comply with the False Claims Act’s requirements. If the government chooses not to intervene, the private individual(s) can proceed independently on behalf of the government. Health care providers that are found to violate the False Claims Act may be subject to substantial monetary fines/penalties as well as face potential exclusion from participating in government health care programs or be required to comply with Corporate Integrity Agreements as a condition of a settlement of a False Claims Act matter. In September 2014, the Criminal Division of the Department of Justice (“DOJ”) announced that all qui tam cases will be shared with their Division to determine if a parallel criminal investigation should be opened. The DOJ has also announced an intention to pursue civil and criminal actions against individuals within a company as well as the corporate entity or entities. In addition, health care facilities are subject to monitoring by state and federal surveyors to ensure compliance with program Conditions of Participation. In the event a facility is found to be out of compliance with a Condition of Participation and unable to remedy the alleged deficiency(s), the facility faces termination from the Medicare and Medicaid programs or compliance with a System Improvement Agreement to remedy deficiencies and ensure compliance. The laws and regulations governing the healthcare industry are complex covering, among other things, government healthcare participation requirements, licensure, certification and accreditation, privacy of patient information, reimbursement for patient services as well as fraud and abuse compliance. These laws and regulations are constantly evolving and expanding. Further, the Legislation has added additional obligations on healthcare providers to report and refund overpayments by government healthcare programs and authorizes the suspension of Medicare and Medicaid payments “pending an investigation of a credible allegation of fraud.” We monitor our business and have developed an ethics and compliance program with respect to these complex laws, rules and regulations. Although we believe our policies, procedures and practices comply with government regulations, there is no assurance that we will not be faced with the sanctions referenced above which include fines, penalties and/or substantial damages, repayment obligations, payment suspensions, licensure revocation, and expulsion from government healthcare programs. Even if we were to ultimately prevail in any action brought against us or our facilities or in responding to any inquiry, such action or inquiry could have a material adverse effect on us. Certain legal matters are described below: Litigation: Knight v. Miller, et. al. In July 2021, a shareholder derivative lawsuit was filed by plaintiff, Robin Knight, in the Chancery Court in Delaware against the members of the Board of Directors of the Company as well as certain officers (C.A. No.: 2021-0581-SG). The Company was named as a nominal defendant. The lawsuit alleges that in March 2020 stock options were awarded with exercise prices that did not reflect the Company’s fundamentals and business prospects, and in anticipation of future market rebound resulting in excessive gains. The lawsuit makes claims of breaches of fiduciary duties, waste of corporate assets, and unjust enrichment. The lawsuit seeks monetary damages allegedly incurred by the Company, disgorgement of the March 2020 stock awards as well as any proceeds derived therefrom and unspecified equitable relief. Defendants deny the allegations. We filed a motion to dismiss the complaint and the court granted part and denied part of our motion. We are uncertain as to potential liability or financial exposure, if any, which may be associated with this matter. The George Washington University v. Universal Health Services, Inc., et. al. In December 2019, The George Washington University (“University”) filed a lawsuit in the Superior Court for the District of Columbia against Universal Health Services, Inc. as well as certain subsidiaries and individuals associated with the ownership and management of The George Washington University Hospital (“GW Hospital”) in Washington, D.C. (case No. 2019 CA 008019 B). The lawsuit claims that UHS failed to provide sufficient financial compensation to the University under the terms of various agreements entered into in 1997 between the University and UHS for the joint venture ownership of GW Hospital. The lawsuit includes claims for breach of contract, breach of fiduciary duty, and unjust enrichment. We deny liability and intend to defend this matter vigorously. We filed a motion to dismiss the complaint. In June 2020, the Court granted the motion in part dismissing the majority of the claims against UHS. At this time, we are uncertain as to potential liability or financial exposure, if any, which may be associated with this matter. During the second quarter of 2022, the parties have reached a settlement, which is subject to regulatory approval from the District of Columbia’s State Health Planning and Development Agency, which would provide for, among other things: (i) the purchase by us of the University’s 20% minority ownership interest in GW Hospital; (ii) a new ground lease related to GW Hospital, and; (iii) annual payments from us to the University for academic mission support and trademark royalties. Although we can provide no assurance that regulatory approval will be granted, the litigation will be dismissed if the settlement is finalized. If finalized, we do not expect this transaction to have a material impact on our future results of operations. Disproportionate Share Hospital Payment Matter: In late September, 2015, many hospitals in Pennsylvania, including certain of our behavioral health care hospitals located in the state, received letters from the Pennsylvania Department of Human Services (the “Department”) demanding repayment of allegedly excess Medicaid Disproportionate Share Hospital payments (“DSH”), primarily consisting of managed care payments characterized as DSH payments, for the federal fiscal year (“FFY”) 2011 amounting to approximately $4 million in the aggregate. Since that time, certain of our behavioral health care hospitals in Pennsylvania have received similar requests for repayment for alleged DSH overpayments for FFYs 2012 through 2015. For FFY 2012, the claimed overpayment amounts to approximately $4 million. For FY 2013, FY 2014 and FY 2015 the initial claimed overpayments and attempted recoupment by the Department were approximately $7 million, $8 million and $7 million, respectively. The Department has agreed to a change in methodology which, upon confirmation of the underlying data being accepted by the Department, could reduce the initial claimed overpayments for FY 2013, FY 2014 and FY 2015 to approximately $2 million, $2 million and $3 million, respectively. We filed administrative appeals for all of our facilities contesting the recoupment efforts for FFYs 2011 through 2015 as we believe the Department’s calculation methodology is inaccurate and conflicts with applicable federal and state laws and regulations. The Department has agreed to postpone the recoupment of the state’s share for FY 2011 to 2013 until all hospital appeals are resolved but started recoupment of the federal share. For FY 2014 and FY 2015, the Department has initiated the recoupment of the alleged overpayments. Starting in FFY 2016, the first full fiscal year after the January 1, 2015 effective date of Medicaid expansion in Pennsylvania, the Department no longer characterized managed care payments received by the hospitals as DSH payments. We can provide no assurance that we will ultimately be successful in our legal and administrative appeals related to the Department’s repayment demands. If our legal and administrative appeals are unsuccessful, our future consolidated results of operations and financial condition could be adversely impacted by these repayments. Boley, et al. v. UHS, et al. Former UHS subsidiary facility employees Mary K. Boley, Kandie Sutter, and Phyllis Johnson, individually and on behalf of a putative class of participants in the UHS Retirement Savings Plan (the “Plan”), filed a complaint in the U.S. District Court for the Eastern District of Pennsylvania against UHS, the Board of Directors of UHS, and the “Plan Committee” of UHS (Case No. 2:20-cv-02644). In subsequent amended complaints, Plaintiffs have dropped the Board of Directors and the “Plan Committee” as defendants and added the UHS Retirement Plans Investment Committee as a new defendant. Plaintiffs allege that UHS breached its fiduciary duties under the Employee Retirement Income Security Act (“ERISA”) by offering to participants in the Plan overly expensive investment options when less expensive investment options were available in the marketplace; caused participants to pay excessive recordkeeping fees associated with the Plan; breached its duty to monitor appointed fiduciaries and: in the alternative, engaged in a “knowing breach of trust” separate from the alleged violations under ERISA. UHS disputes Plaintiffs’ allegations and is actively defending against Plaintiffs’ claims. UHS’ motion for partial dismissal of Plaintiffs’ claims was denied by the Court. In March 2021, the Court granted Plaintiffs’ motion for class certification. Although the Third Circuit Court of Appeal agreed to hear an appeal of the trial court’s order granting class certification, the appeal was denied and the class certification was affirmed. As a result, the stay of the case in the trial court pending conclusion of the appellate proceedings has been lifted. We are uncertain as to potential liability or financial exposure, if any, which may be associated with this matter. We maintain commercial insurance coverage for claims of this nature, subject to specified deductibles and limitations. Other Matters: Various other suits, claims and investigations, including government subpoenas, arising against, or issued to, us are pending and additional such matters may arise in the future. Management will consider additional disclosure from time to time to the extent it believes such matters may be or become material. The outcome of any current or future litigation or governmental or internal investigations, including the matters described above, cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that we conclude it is probable that a liability has been incurred and the amount of the loss can be reasonably estimated. No estimate of the possible loss or range of loss in excess of amounts accrued, if any, can be made at this time regarding the matters described above or that are otherwise pending because the inherently unpredictable nature of legal proceedings may be exacerbated by various factors, including, but not limited to: (i) the damages sought in the proceedings are unsubstantiated or indeterminate; (ii) discovery is not complete; (iii) the matter is in its early stages; (iv) the matters present legal uncertainties; (v) there are significant facts in dispute; (vi) there are a large number of parties, or; (vii) there is a wide range of potential outcomes. It is possible that the outcome of these matters could have a material adverse impact on our future results of operations, financial position, cash flows and, potentially, our reputation.

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Reporting	(7) Segment Reporting Our reportable operating segments consist of acute care hospital services and behavioral health care services. The “Other” segment column below includes centralized services including, but not limited to, information technology, purchasing, reimbursement, accounting and finance, taxation, legal, advertising and design and construction. The chief operating decision making group for our acute care services and behavioral health care services is comprised of our President and Chief Executive Officer and the Presidents of each operating segment. The Presidents for each operating segment also manage the profitability of each respective segment’s various facilities. The operating segments are managed separately because each operating segment represents a business unit that offers different types of healthcare services or operates in different healthcare environments. The accounting policies of the operating segments are the same as those described in the summary of significant accounting policies included in our Annual Report on Form 10-K for the year ended December 31, 2021. The corporate overhead allocations, as reflected below, are utilized for internal reporting purposes and are comprised of each period’s projected corporate-level operating expenses (excluding interest expense). The overhead expenses are captured and allocated directly to each segment to the extent possible, and overhead expenses incurred on behalf of both segments are captured and allocated to each segment based upon each segment’s respective percentage of total operating expenses. Three months ended June 30, 2022 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 9,706,731 $ 2,561,553 $ - $ 12,268,284 Gross outpatient revenues $ 6,206,039 $ 268,489 $ - $ 6,474,528 Total net revenues $ 1,875,516 $ 1,433,920 $ 13,971 $ 3,323,407 Income/(loss) before allocation of corporate overhead and income taxes $ 95,059 $ 249,958 $ (135,287 ) $ 209,730 Allocation of corporate overhead $ (63,213 ) $ (45,063 ) $ 108,276 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 31,846 $ 204,895 $ (27,011 ) $ 209,730 Total assets as of June 30, 2022 $ 5,785,470 $ 7,251,966 $ 258,667 $ 13,296,103 Six months ended June 30, 2022 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 19,945,962 $ 4,998,027 $ - $ 24,943,989 Gross outpatient revenues $ 11,981,578 $ 525,602 $ - $ 12,507,180 Total net revenues $ 3,787,832 $ 2,800,387 $ 28,144 $ 6,616,363 Income/(loss) before allocation of corporate overhead and income taxes $ 243,739 $ 455,746 $ (289,772 ) $ 409,713 Allocation of corporate overhead $ (125,497 ) $ (90,064 ) $ 215,561 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 118,242 $ 365,682 $ (74,211 ) $ 409,713 Total assets as of June 30, 2022 $ 5,785,470 $ 7,251,966 $ 258,667 $ 13,296,103 Three months ended June 30, 2021 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 8,662,335 $ 2,527,776 $ 0 $ 11,190,111 Gross outpatient revenues $ 5,357,888 $ 266,328 $ 0 $ 5,624,216 Total net revenues $ 1,754,431 $ 1,431,497 $ 11,952 $ 3,197,880 Income/(loss) before allocation of corporate overhead and income taxes $ 218,663 $ 324,577 $ (116,442 ) $ 426,798 Allocation of corporate overhead $ (58,227 ) $ (43,099 ) $ 101,326 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 160,436 $ 281,478 $ (15,116 ) $ 426,798 Total assets as of June 30, 2021 $ 5,162,252 $ 7,159,426 $ 490,957 $ 12,812,635 Six months ended June 30, 2021 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 17,781,519 $ 5,001,341 $ 0 $ 22,782,860 Gross outpatient revenues $ 9,938,608 $ 513,092 $ 0 $ 10,451,700 Total net revenues $ 3,448,973 $ 2,746,834 $ 15,060 $ 6,210,867 Income/(loss) before allocation of corporate overhead and income taxes $ 391,781 $ 555,902 $ (248,008 ) $ 699,675 Allocation of corporate overhead $ (116,334 ) $ (86,049 ) $ 202,383 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 275,447 $ 469,853 $ (45,625 ) $ 699,675 Total assets as of June 30, 2021 $ 5,162,252 $ 7,159,426 $ 490,957 $ 12,812,635 (a) Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $173 million and $172 million for the three-month periods ended June 30, 2022 and 2021, respectively, and approximately $349 million and $337 million for the six-month periods ended June 30, 2022 and 2021, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.220 billion and $1.369 billion as of June 30, 2022 and 2021, respectively.

Earnings Per Share Data ("EPS")

Earnings Per Share Data ("EPS") and Stock Based Compensation	6 Months Ended
	Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Earnings Per Share Data ("EPS") and Stock Based Compensation	(8) Earnings Per Share Data (“EPS”) and Stock Based Compensation Basic earnings per share are based on the weighted average number of common shares outstanding during the period. Diluted earnings per share are based on the weighted average number of common shares outstanding during the period adjusted to give effect to common stock equivalents. The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Basic and Diluted: Net income attributable to UHS $ 164,062 $ 325,024 $ 317,975 $ 534,115 Less: Net income attributable to unvested restricted share grants (164 ) (661 ) (413 ) (1,213 ) Net income attributable to UHS – basic and diluted $ 163,898 $ 324,363 $ 317,562 $ 532,902 Weighted average number of common shares - basic 73,682 84,224 74,356 84,503 Net effect of dilutive stock options and grants based on the treasury stock method 753 1,400 882 1,207 Weighted average number of common shares and equivalents - diluted 74,435 85,624 75,238 85,710 Earnings per basic share attributable to UHS: $ 2.22 $ 3.85 $ 4.27 $ 6.31 Earnings per diluted share attributable to UHS: $ 2.20 $ 3.79 $ 4.22 $ 6.22 The “Net effect of dilutive stock options and grants based on the treasury stock method”, for all periods presented above, excludes certain outstanding stock options applicable to each period since the effect would have been anti-dilutive. The excluded weighted-average stock options totaled 5.6 million for the three and six-months ended June 30, 2022. The excluded weighted-average stock options totaled 4.2 million for the three months ended June 30, 2021 and 4.4 million for the six months ended June 30, 2021. All classes of our common stock have the same dividend rights. Stock-Based Compensation: During the three-month periods ended June 30, 2022 and 2021, pre-tax compensation costs of $17.6 million and $15.5 million, respectively, was recognized related to outstanding stock options. During the six-month periods ended June 30, 2022 and 2021, pre-tax compensation costs of $32.8 million and $30.2 million, respectively, was recognized related to outstanding stock options. In addition, during the three-month periods ended June 30, 2022 and 2021, pre-tax compensation cost of approximately $4.7 million and $3.2 million, respectively, was recognized related to restricted stock awards, restricted stock units and performance based restricted stock units. During the six-month periods ended June 30, 2022 and 2021, pre-tax compensation cost of approximately $8.1 million and $6.1 million, respectively, was recognized related to restricted stock awards, restricted stock units and performance based restricted stock units. As of June 30, 2022 there was approximately $191.7 million of unrecognized compensation cost related to unvested options, restricted stock awards, restricted stock units and performance based restricted stock units which is expected to be recognized over the remaining weighted average vesting period of 3.0 years. There were 1,821,573 stock options granted during the first six months of 2022 with a weighted-average grant date fair value of $45.67 per option. There were an aggregate of 248,684 restricted units granted during the first six months of 2022, including 73,782 performance based restricted stock units, with a weighted-average grant date fair value of $142.97 per share. The expense associated with stock-based compensation arrangements is a non-cash charge. In the Condensed Consolidated Statements of Cash Flows, stock-based compensation expense is an adjustment to reconcile net income to cash provided by operating activities and aggregated to $41.6 million and $37.0 million during the six-month periods ended June 30, 2022 and 2021.

Dispositions and acquisitions

Dispositions and acquisitions	6 Months Ended
	Jun. 30, 2022
Business Combinations [Abstract]
Dispositions and acquisitions	(9) Dispositions and acquisitions Six-month period ended June 30, 2022: Acquisitions: During the first six months of 2022, we spent $12 million on the acquisition of businesses and property. Divestitures: During the first six months of 2022, we received $10 million from the sales of assets and businesses. Six-month period ended June 30, 2021: Acquisitions: During the first six months of 2021, there were no acquisitions. Divestitures: During the first six months of 2021, we received $21 million from the sale of our equity interest in a business.

Dividends

Dividends	6 Months Ended
	Jun. 30, 2022
Earnings Per Share [Abstract]
Dividends	(10) Dividends We declared and paid dividends of $14.7 million, or $.20 per share, during the second quarter of 2022 and $16.8 million, or $.20 per share, during the second quarter of 2021. We declared and paid dividends of $29.4 million, or $.40 per share during the six-month period ended June 30, 2022 and $33.8 million, or $.40 per share, during the six-month period ended June 30, 2021. Included in the amounts above were dividend equivalents applicable to unvested restricted stock units which were accrued during 2022 and 2021 and will be, or were, paid upon vesting of the restricted stock unit.

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Tax Disclosure [Abstract]
Income Taxes	(11) Income Taxes Our effective income tax rates were 24.3% and 23.8% during the three-month periods ended June 30, 2022, and 2021, respectively, and 24.4% and 23.6% during the six-month periods ended June 30, 2022, and 2021, respectively. The increase in the effective tax rates during the three and six-month periods ended June 30, 2022, as compared to the comparable periods of 2021, was primarily due to the decreases in net income attributable to noncontrolling interests during the three and six-month periods ended June 30, 2022, as compared to the comparable periods of 2021. The global intangible low-taxed income (“GILTI”) provisions from the TCJA-17 require the inclusion of the earnings of certain foreign subsidiaries in excess of an acceptable rate of return on certain assets of the respective subsidiaries in our U.S. tax return for tax years beginning after December 31, 2017. An accounting policy election was made during 2018 to treat taxes related to GILTI as a period cost when the tax is incurred. We recorded a GILTI tax provision of zero for the six months ended June 30, 2022 and 2021. As of January 1, 2022, our unrecognized tax benefits were approximately $2 million. The amount, if recognized, that would favorably affect the effective tax rate is approximately $2 million. During the six months ended June 30, 2022, changes to the estimated liabilities for uncertain tax positions (including accrued interest) relating to tax positions taken during prior and current periods did not have a material impact on our financial statements. We recognize accrued interest and penalties associated with uncertain tax positions as part of the tax provision. As of June 30, 2022, we have less than $1 million of accrued interest and penalties. The U.S. federal statute of limitations remains open for 2018 and subsequent years. Foreign and U.S. state and local jurisdictions have statutes of limitations generally ranging from 3 to 4 years. The statute of limitations on certain jurisdictions could expire within the next twelve months. It is reasonably possible that the amount of uncertain tax benefits will change during the next 12 months, however, it is anticipated that any such change, if it were to occur, would not have a material impact on our results of operations. We operate in multiple jurisdictions with varying tax laws. We are subject to audits by any of these taxing authorities. Our tax returns have been examined by the Internal Revenue Service (“IRS”) through the year ended December 31, 2006. We believe that adequate accruals have been provided for federal, foreign and state taxes.

Revenue

Revenue	6 Months Ended
	Jun. 30, 2022
Revenue From Contract With Customer [Abstract]
Revenue	(12) Revenue The company recognizes revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. Our estimate for amounts not expected to be collected based on historical experience will continue to be recognized as a reduction to net revenue. However, subsequent changes in estimate of collectability due to a change in the financial status of a payer, for example a bankruptcy, will be recognized as bad debt expense in operating charges. The performance obligation is separately identifiable from other promises in the customer contract. As the performance obligations are met (i.e.: room, board, ancillary services, level of care), revenue is recognized based upon allocated transaction price. . In assessing collectability, we have elected the portfolio approach. This portfolio approach is being used as we have large volume of similar contracts with similar classes of customers. We reasonably expect that the effect of applying a portfolio approach to a group of contracts would not differ materially from considering each contract separately. Management’s judgment to group the contracts by portfolio is based on the payment behavior expected in each portfolio category. As a result, aggregating all of the contracts (which are at the patient level) by the particular payer or group of payers, will result in the recognition of the same amount of revenue as applying the analysis at the individual patient level. We group our revenues into categories based on payment behaviors. Each component has its own reimbursement structure which allows us to disaggregate the revenue into categories that share the nature and timing of payments. The other patient revenue consists primarily of self-pay, government-funded non-Medicaid, and other. The following table disaggregates our revenue by major source for the three and six-month periods ended June 30, 2022 and 2021 (in thousands): For the three months ended June 30, 2022 Acute Care Behavioral Health Other Total Medicare $ 318,166 17 % $ 83,350 6 % $ 401,516 12 % Managed Medicare 306,585 16 % 70,877 5 % 377,462 11 % Medicaid 184,098 10 % 183,911 13 % 368,009 11 % Managed Medicaid 162,092 9 % 364,171 25 % 526,263 16 % Managed Care (HMO and PPOs) 627,475 33 % 376,011 26 % 1,003,486 30 % UK Revenue 0 0 % 173,231 12 % 173,231 5 % Other patient revenue and adjustments, net 74,123 4 % 125,995 9 % 200,118 6 % Other non-patient revenue 202,977 11 % 56,374 4 % 13,971 273,322 8 % Total Net Revenue $ 1,875,516 100 % $ 1,433,920 100 % $ 13,971 3,323,407 100 % For the six months ended June 30, 2022 Acute Care Behavioral Health Other Total Medicare $ 655,275 17 % $ 162,862 6 % $ 818,137 12 % Managed Medicare 638,833 17 % 134,727 5 % 773,560 12 % Medicaid 339,934 9 % 359,314 13 % 699,248 11 % Managed Medicaid 333,729 9 % 698,336 25 % 1,032,065 16 % Managed Care (HMO and PPOs) 1,266,370 33 % 741,216 26 % 2,007,586 30 % UK Revenue 0 0 % 349,323 12 % 349,323 5 % Other patient revenue and adjustments, net 166,233 4 % 246,728 9 % 412,961 6 % Other non-patient revenue 387,458 10 % 107,881 4 % 28,144 523,483 8 % Total Net Revenue $ 3,787,832 100 % $ 2,800,387 100 % $ 28,144 $ 6,616,363 100 % For the three months ended June 30, 2021 Acute Care Behavioral Health Other Total Medicare $ 308,211 18 % $ 92,727 6 % $ 400,938 13 % Managed Medicare 274,393 16 % 61,532 4 % 335,925 11 % Medicaid 169,705 10 % 227,524 16 % 397,229 12 % Managed Medicaid 161,261 9 % 334,202 23 % 495,463 15 % Managed Care (HMO and PPOs) 588,806 34 % 372,146 26 % 960,952 30 % UK Revenue 0 0 % 172,220 12 % 172,220 5 % Other patient revenue and adjustments, net 84,157 5 % 128,944 9 % 213,101 7 % Other non-patient revenue 167,898 10 % 42,202 3 % 11,952 222,052 7 % Total Net Revenue $ 1,754,431 100 % $ 1,431,497 100 % $ 11,952 $ 3,197,880 100 % For the six months ended June 30, 2021 Acute Care Behavioral Health Other Total Medicare $ 643,724 19 % $ 181,219 7 % $ 824,943 13 % Managed Medicare 549,953 16 % 119,074 4 % 669,027 11 % Medicaid 281,346 8 % 380,664 14 % 662,010 11 % Managed Medicaid 296,759 9 % 668,960 24 % 965,719 16 % Managed Care (HMO and PPOs) 1,187,616 34 % 720,890 26 % 1,908,506 31 % UK Revenue 0 0 % 336,886 12 % 336,886 5 % Other patient revenue and adjustments, net 178,407 5 % 249,227 9 % 427,634 7 % Other non-patient revenue 311,168 9 % 89,914 3 % 15,060 416,142 7 % Total Net Revenue $ 3,448,973 100 % $ 2,746,834 100 % $ 15,060 $ 6,210,867 100 %

Lease Accounting

Lease Accounting	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Lease Accounting	(13) Lease Accounting Our operating leases are primarily for real estate, including certain acute care facilities, off-campus outpatient facilities, medical office buildings, and corporate and other administrative offices. Our real estate lease agreements typically have initial terms of five to ten years. These real estate leases may include one or more options to renew, with renewals that can extend the lease term from five to ten years. The exercise of lease renewal options is at our sole discretion. When determining the lease term, we included options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Five of our hospital facilities are held under operating leases with Universal Health Realty Income Trust with two hospital terms expiring in 2026, two expiring in 2033 and one expiring in 2040 (see Note 2 for additional disclosure). We are also the lessee of the real property of certain facilities from unrelated third parties. Supplemental cash flow information related to leases for the six-month periods ended June 30, 2022 and 2021 are as follows (in thousands): Six months ended June 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 61,964 $ 59,818 Operating cash flows from finance leases $ 2,000 $ 2,352 Financing cash flows from finance leases $ 1,798 $ 1,589 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 27,930 $ 12,322 Finance leases $ 1,066 $ 7,690

Recent Accounting Standards

Recent Accounting Standards	6 Months Ended
	Jun. 30, 2022
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Standards	(14) Recent Accounting Standards In November 2021, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2021-10, “Government Assistance (Topic 832)” (“ASU 2021-10”). ASU 2021-10 provides guidance to increase the transparency of government assistance including the disclosure of (1) the types of assistance, (2) an entity’s accounting for the assistance, and (3) the effect of the assistance on an entity’s financial statements. ASU 2021-10 applies to all business entities that account for a transaction with a government by applying a grant or contribution accounting model by analogy to other accounting guidance (for example, a grant model within IAS 20, Accounting for Government Grants and Disclosure of Government Assistance, or Subtopic 958-605, Not-For-Profit Entities—Revenue Recognition). ASU 2021-10 is effective for fiscal years beginning after December 15, 2021. Early adoption is permitted. The adoption of this standard is not expected to have a material impact on our results of operations, cash flows or financial position. In March 2020, the FASB issued ASU 2020-04, “Facilitation of the Effects of Reference Rate Reform on Financial Reporting.” The ASU is intended to provide temporary optional expedients and exceptions to the US GAAP guidance on contract modifications and hedge accounting to ease the financial reporting burdens related to the expected market transition from LIBOR and other interbank offered rates to alternative reference rates. The pronouncement is effective immediately and can be applied to contract modifications through December 31, 2022. To the extent that, prior to December 31, 2022, the Company enters into any contract modifications for which the optional expedients are applied, the adoption of this standard is not expected to have a material impact From time to time, new accounting guidance is issued by the FASB or other standard setting bodies that is adopted by the Company as of the effective date or, in some cases where early adoption is permitted, in advance of the effective date. The Company has assessed the recently issued guidance that is not yet effective and, unless otherwise indicated above, believes the new guidance will not have a material impact on our results of operations, cash flows or financial position.

Relationship with Universal H_2

Relationship with Universal Health Realty Income Trust and Other Related Party Transactions (Tables)	6 Months Ended
	Jun. 30, 2022
Related Party Transactions [Abstract]
Remaining Renewal Options and Terms for Each of Three Hospital Facilities Leased from Trust	The table below provides certain details for each of the hospitals leased from the Trust as of June 30, 2022: Hospital Name Annual Minimum Rent End of Lease Term Renewal Term (years) McAllen Medical Center $ 5,485,000 December, 5 (a) Wellington Regional Medical Center $ 6,319,000 December, 5 (b) Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services $ 3,895,000 December, 35 (c) Canyon Creek Behavioral Health $ 1,670,000 December, 35 (c) Clive Behavioral Health Hospital $ 2,628,000 December, 50 (d) (a) We have one 5-year renewal option at existing lease rates (through 2031). (b) We have one 5-year renewal options at fair market value lease rates (through 2031). Upon the December 31, 2021 expiration of the lease on Wellington Regional Medical Center, a wholly-owned subsidiary of ours exercised its fair market value renewal option and renewed the lease for a 5-year term scheduled to expire on December 31, 2026. Effective January 1, 2022, the annual fair market value lease rate for this hospital is $6.3 million (there is no longer a bonus rental component of the lease payment). Beginning on January 1, 2023, and thereafter on each January 1 st (c) We have seven 5-year (d) This facility is operated by a joint venture in which we are the managing, majority member and an unrelated third-party holds a minority ownership interest. The joint venture has three, 10-year renewal options at computed lease rates as stipulated in the lease (2041 through 2070) and two additional, 10-year renewal options at fair market values lease rates (2071 through 2090). Beginning in January, 2022, and thereafter in each January through 2040 (and potentially through 2070 if three, 10-year renewal options are exercised), the annual rental will increase by 2.75% on a cumulative and compounded basis.

Treasury (Tables)

Treasury (Tables)	6 Months Ended
	Jun. 30, 2022
Equity [Abstract]
Summary of Effects of Foreign Currency Foreign Exchange Contracts on Result of Operations	The following table presents the effects of our foreign currency foreign exchange contracts on our results of operations for the three and six-month periods ended June 30, 2022 and 2021 (in thousands): Gain/(Loss) recognized in AOCI Three months ended Six months ended June 30, June 30, June 30, June 30, 2022 2021 2022 2021 Net Investment Hedge relationships Foreign currency foreign exchange contracts $ 64,464 $ (9,917 ) $ 81,576 $ (31,031 )
Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows	Cash, cash equivalents, and restricted cash as reported in the condensed consolidated statements of cash flows are presented separately on our condensed consolidated balance sheets as follows (in thousands): June 30, June 30, December 31, 2022 2021 2021 Cash and cash equivalents $ 132,658 $ 199,017 $ 115,301 Restricted cash (a) 69,253 54,671 63,633 Total cash, cash equivalents and restricted cash $ 201,911 $ 253,688 $ 178,934 (a) Restricted cash is included in other assets on the accompanying consolidated balance sheet.

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Disclosures [Abstract]
Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis	The following tables present the assets and liabilities recorded at fair value on a recurring basis: Balance at Balance Sheet Basis of Fair Value Measurement (in thousands) June 30, 2022 Location Level 1 Level 2 Level 3 Assets: Money market mutual funds 85,037 Other assets 85,037 Certificates of deposit 2,200 Other assets 2,200 Equity securities 79,662 Other assets 79,662 Deferred compensation assets 38,690 Other assets 38,690 Foreign currency exchange contracts 1,602 Other current assets 1,602 $ 207,191 $ 203,389 $ 3,802 - Liabilities: Deferred compensation liability 38,690 Other noncurrent liabilities 38,690 $ 38,690 $ 38,690 - - Balance at Balance Sheet Basis of Fair Value Measurement (in thousands) December 31, 2021 Location Level 1 Level 2 Level 3 Assets: Money market mutual funds 79,900 Other assets 79,900 Certificates of deposit 2,300 Other assets 2,300 Equity securities 91,919 Other assets 91,919 Deferred compensation assets 45,759 Other assets 45,759 Foreign currency exchange contracts 1,357 Other current assets 1,357 $ 221,235 $ 217,578 $ 3,657 - Liabilities: Deferred compensation liability 45,759 Other noncurrent liabilities $ 45,759 $ 45,759 $ 45,759 - -

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting [Abstract]
Segment Reporting	Three months ended June 30, 2022 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 9,706,731 $ 2,561,553 $ - $ 12,268,284 Gross outpatient revenues $ 6,206,039 $ 268,489 $ - $ 6,474,528 Total net revenues $ 1,875,516 $ 1,433,920 $ 13,971 $ 3,323,407 Income/(loss) before allocation of corporate overhead and income taxes $ 95,059 $ 249,958 $ (135,287 ) $ 209,730 Allocation of corporate overhead $ (63,213 ) $ (45,063 ) $ 108,276 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 31,846 $ 204,895 $ (27,011 ) $ 209,730 Total assets as of June 30, 2022 $ 5,785,470 $ 7,251,966 $ 258,667 $ 13,296,103 Six months ended June 30, 2022 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 19,945,962 $ 4,998,027 $ - $ 24,943,989 Gross outpatient revenues $ 11,981,578 $ 525,602 $ - $ 12,507,180 Total net revenues $ 3,787,832 $ 2,800,387 $ 28,144 $ 6,616,363 Income/(loss) before allocation of corporate overhead and income taxes $ 243,739 $ 455,746 $ (289,772 ) $ 409,713 Allocation of corporate overhead $ (125,497 ) $ (90,064 ) $ 215,561 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 118,242 $ 365,682 $ (74,211 ) $ 409,713 Total assets as of June 30, 2022 $ 5,785,470 $ 7,251,966 $ 258,667 $ 13,296,103 Three months ended June 30, 2021 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 8,662,335 $ 2,527,776 $ 0 $ 11,190,111 Gross outpatient revenues $ 5,357,888 $ 266,328 $ 0 $ 5,624,216 Total net revenues $ 1,754,431 $ 1,431,497 $ 11,952 $ 3,197,880 Income/(loss) before allocation of corporate overhead and income taxes $ 218,663 $ 324,577 $ (116,442 ) $ 426,798 Allocation of corporate overhead $ (58,227 ) $ (43,099 ) $ 101,326 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 160,436 $ 281,478 $ (15,116 ) $ 426,798 Total assets as of June 30, 2021 $ 5,162,252 $ 7,159,426 $ 490,957 $ 12,812,635 Six months ended June 30, 2021 Acute Care Hospital Services Behavioral Health Services (a) Other Total Consolidated (Amounts in thousands) Gross inpatient revenues $ 17,781,519 $ 5,001,341 $ 0 $ 22,782,860 Gross outpatient revenues $ 9,938,608 $ 513,092 $ 0 $ 10,451,700 Total net revenues $ 3,448,973 $ 2,746,834 $ 15,060 $ 6,210,867 Income/(loss) before allocation of corporate overhead and income taxes $ 391,781 $ 555,902 $ (248,008 ) $ 699,675 Allocation of corporate overhead $ (116,334 ) $ (86,049 ) $ 202,383 $ 0 Income/(loss) after allocation of corporate overhead and before income taxes $ 275,447 $ 469,853 $ (45,625 ) $ 699,675 Total assets as of June 30, 2021 $ 5,162,252 $ 7,159,426 $ 490,957 $ 12,812,635 (a) Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $173 million and $172 million for the three-month periods ended June 30, 2022 and 2021, respectively, and approximately $349 million and $337 million for the six-month periods ended June 30, 2022 and 2021, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.220 billion and $1.369 billion as of June 30, 2022 and 2021, respectively.

Earnings Per Share Data ("EPS_2

Earnings Per Share Data ("EPS") and Stock Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Computation of Basic and Diluted Earnings per Share	The following table sets forth the computation of basic and diluted earnings per share for the periods indicated (in thousands, except per share data): Three months ended June 30, Six months ended June 30, 2022 2021 2022 2021 Basic and Diluted: Net income attributable to UHS $ 164,062 $ 325,024 $ 317,975 $ 534,115 Less: Net income attributable to unvested restricted share grants (164 ) (661 ) (413 ) (1,213 ) Net income attributable to UHS – basic and diluted $ 163,898 $ 324,363 $ 317,562 $ 532,902 Weighted average number of common shares - basic 73,682 84,224 74,356 84,503 Net effect of dilutive stock options and grants based on the treasury stock method 753 1,400 882 1,207 Weighted average number of common shares and equivalents - diluted 74,435 85,624 75,238 85,710 Earnings per basic share attributable to UHS: $ 2.22 $ 3.85 $ 4.27 $ 6.31 Earnings per diluted share attributable to UHS: $ 2.20 $ 3.79 $ 4.22 $ 6.22

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue From Contract With Customer [Abstract]
Schedule of Disaggregates Revenue by Major Source	The following table disaggregates our revenue by major source for the three and six-month periods ended June 30, 2022 and 2021 (in thousands): For the three months ended June 30, 2022 Acute Care Behavioral Health Other Total Medicare $ 318,166 17 % $ 83,350 6 % $ 401,516 12 % Managed Medicare 306,585 16 % 70,877 5 % 377,462 11 % Medicaid 184,098 10 % 183,911 13 % 368,009 11 % Managed Medicaid 162,092 9 % 364,171 25 % 526,263 16 % Managed Care (HMO and PPOs) 627,475 33 % 376,011 26 % 1,003,486 30 % UK Revenue 0 0 % 173,231 12 % 173,231 5 % Other patient revenue and adjustments, net 74,123 4 % 125,995 9 % 200,118 6 % Other non-patient revenue 202,977 11 % 56,374 4 % 13,971 273,322 8 % Total Net Revenue $ 1,875,516 100 % $ 1,433,920 100 % $ 13,971 3,323,407 100 % For the six months ended June 30, 2022 Acute Care Behavioral Health Other Total Medicare $ 655,275 17 % $ 162,862 6 % $ 818,137 12 % Managed Medicare 638,833 17 % 134,727 5 % 773,560 12 % Medicaid 339,934 9 % 359,314 13 % 699,248 11 % Managed Medicaid 333,729 9 % 698,336 25 % 1,032,065 16 % Managed Care (HMO and PPOs) 1,266,370 33 % 741,216 26 % 2,007,586 30 % UK Revenue 0 0 % 349,323 12 % 349,323 5 % Other patient revenue and adjustments, net 166,233 4 % 246,728 9 % 412,961 6 % Other non-patient revenue 387,458 10 % 107,881 4 % 28,144 523,483 8 % Total Net Revenue $ 3,787,832 100 % $ 2,800,387 100 % $ 28,144 $ 6,616,363 100 % For the three months ended June 30, 2021 Acute Care Behavioral Health Other Total Medicare $ 308,211 18 % $ 92,727 6 % $ 400,938 13 % Managed Medicare 274,393 16 % 61,532 4 % 335,925 11 % Medicaid 169,705 10 % 227,524 16 % 397,229 12 % Managed Medicaid 161,261 9 % 334,202 23 % 495,463 15 % Managed Care (HMO and PPOs) 588,806 34 % 372,146 26 % 960,952 30 % UK Revenue 0 0 % 172,220 12 % 172,220 5 % Other patient revenue and adjustments, net 84,157 5 % 128,944 9 % 213,101 7 % Other non-patient revenue 167,898 10 % 42,202 3 % 11,952 222,052 7 % Total Net Revenue $ 1,754,431 100 % $ 1,431,497 100 % $ 11,952 $ 3,197,880 100 % For the six months ended June 30, 2021 Acute Care Behavioral Health Other Total Medicare $ 643,724 19 % $ 181,219 7 % $ 824,943 13 % Managed Medicare 549,953 16 % 119,074 4 % 669,027 11 % Medicaid 281,346 8 % 380,664 14 % 662,010 11 % Managed Medicaid 296,759 9 % 668,960 24 % 965,719 16 % Managed Care (HMO and PPOs) 1,187,616 34 % 720,890 26 % 1,908,506 31 % UK Revenue 0 0 % 336,886 12 % 336,886 5 % Other patient revenue and adjustments, net 178,407 5 % 249,227 9 % 427,634 7 % Other non-patient revenue 311,168 9 % 89,914 3 % 15,060 416,142 7 % Total Net Revenue $ 3,448,973 100 % $ 2,746,834 100 % $ 15,060 $ 6,210,867 100 %

Lease Accounting (Tables)

Lease Accounting (Tables)	6 Months Ended
	Jun. 30, 2022
Leases [Abstract]
Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases for the six-month periods ended June 30, 2022 and 2021 are as follows (in thousands): Six months ended June 30, 2022 2021 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 61,964 $ 59,818 Operating cash flows from finance leases $ 2,000 $ 2,352 Financing cash flows from finance leases $ 1,798 $ 1,589 Right-of-use assets obtained in exchange for lease obligations: Operating leases $ 27,930 $ 12,322 Finance leases $ 1,066 $ 7,690

General - Additional Informatio

General - Additional Information (Detail) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Mar. 31, 2021	Jun. 30, 2021	Mar. 31, 2021
Disclosure of General Information [Line Items]
Additional funds received from government by CARES Act			$ 189
Return of funds by CARES Act to government		$ 189
Medicare Accelerated and Advance Payment Program
Disclosure of General Information [Line Items]
Medicare accelerated payments received	$ 695

Relationship with Universal H_3

Relationship with Universal Health Realty Income Trust and Other Related Party Transactions - Additional Information (Detail)	1 Months Ended	3 Months Ended				6 Months Ended		9 Months Ended	12 Months Ended
	Jan. 31, 2022 USD ($) Bed SquareFoot	Jun. 30, 2022 USD ($) Facility Hospital	Jun. 30, 2021 USD ($) Hospital	Sep. 30, 2020 USD ($)	Dec. 31, 2013	Jun. 30, 2022 USD ($) Facility Hospital Bed	Jun. 30, 2021 USD ($) Hospital	Sep. 30, 2021 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020	Dec. 31, 2019
Related Party Transaction [Line Items]
Net revenues		$ 3,323,407,000	$ 3,197,880,000			$ 6,616,363,000	$ 6,210,867,000
Lease and rental expense		$ 31,773,000	29,149,000			$ 63,811,000	$ 60,473,000
Number of hospital facilities | Hospital						5
Chief Executive Officer
Related Party Transaction [Line Items]
Estimated payments to acquire life insurance policies						$ 28,000,000
Payments to acquire life insurance policies, net										$ 1,000,000
Chief Executive Officer | Scenario Forecast
Related Party Transaction [Line Items]
Payments to acquire life insurance policies, net									$ 1,000,000
Chief Executive Officer | Trust Owned by CEO
Related Party Transaction [Line Items]
Estimated payments to acquire life insurance policies						9,000,000
Minimum | Chief Executive Officer
Related Party Transaction [Line Items]
Estimated death benefit proceeds						$ 37,000,000
Relationship with Universal Health Realty Income Trust
Related Party Transaction [Line Items]
Trust outstanding shares held, percentage		5.70%				5.70%
Percentage of advisory fee on average invested real estate assets						0.70%	0.70%			0.70%	0.70%	0.70%
Pre-tax share of income from the Trust		$ 307,000	394,000			$ 607,000	$ 701,000
Dividends received from the Trust		559,000	551,000			1,100,000	1,100,000
Carrying value of investment in Trust		8,900,000				8,900,000				$ 9,400,000
Market value of investment in Trust		41,900,000				41,900,000				46,800,000
Financial liability included in debt		82,500,000				82,500,000
Lease and rental expense		$ 5,000,000	$ 4,000,000			$ 10,000,000	$ 8,000,000
Number of hospital facilities | Hospital		4	3			4	3
Notice period on renewal of lease						90 days
Period of rights of refusal to leased facilities						180 days
Number of free-standing emergency departments to be acquired | Facility		2				2
Number of square feet to be constructed | SquareFoot	86,000
Number of beds available in acute care hospital | Bed	170
Percentage of master lease rentable square feet	68%
Relationship with Universal Health Realty Income Trust | Minimum
Related Party Transaction [Line Items]
Lease and rental expense	$ 1,300,000
Relationship with Universal Health Realty Income Trust | Minimum | Limited Liability Companies
Related Party Transaction [Line Items]
Non-controlling ownership interests by subsidiaries		95%				95%
Relationship with Universal Health Realty Income Trust | Maximum | Limited Liability Companies
Related Party Transaction [Line Items]
Non-controlling ownership interests by subsidiaries		100%				100%
Relationship with Universal Health Realty Income Trust | Aiken, South Carolina | Behavioral Health Care Facility
Related Party Transaction [Line Items]
Lease and rental expense		$ 657,000	$ 622,000			$ 1,300,000	$ 1,200,000
Notice period on renewal of lease						270 days
Period of rights of refusal to leased facilities						30 days
Number of bed available in behavioral health care facility | Bed						100
Relationship with Universal Health Realty Income Trust | Aiken Regional Medical Center
Related Party Transaction [Line Items]
Lease rent receivable						$ 3,900,000
Relationship with Universal Health Realty Income Trust | Canyon Creek Behavioral Health
Related Party Transaction [Line Items]
Lease rent receivable						1,800,000
Relationship with Universal Health Realty Income Trust | Aiken Regional Medical Center and Canyon Creek Behavioral Health
Related Party Transaction [Line Items]
Lease rent receivable						$ 5,700,000
Number of facilities leased | Facility						2
Relationship with Universal Health Realty Income Trust | Aiken Regional Medical Center and Canyon Creek Behavioral Health | Bonus Rental
Related Party Transaction [Line Items]
Lease revenue						$ 0
Relationship with Universal Health Realty Income Trust | Asset Purchase and Sale Agreement | Subsidiaries
Related Party Transaction [Line Items]
Cash received for sale of real estate asset										4,100,000
Relationship with Universal Health Realty Income Trust | Asset Purchase and Sale Agreement | Subsidiaries | Inland Valley Campus of Southwest Healthcare System | Wildomar, California
Related Party Transaction [Line Items]
Fair market value of real estate assets received										79,600,000
Relationship with Universal Health Realty Income Trust | Asset Purchase and Sale Agreement | Subsidiaries | Aiken Regional Medical Center | Aiken South Carolina
Related Party Transaction [Line Items]
Fair market value of real estate assets sold										57,700,000
Relationship with Universal Health Realty Income Trust | Asset Purchase and Sale Agreement | Subsidiaries | Canyon Creek Behavioral Health | Temple, Texas
Related Party Transaction [Line Items]
Fair market value of real estate assets sold										26,000,000
Relationship with Universal Health Realty Income Trust | Asset Purchase and Sale Agreement | Subsidiaries | Aiken Regional Medical Center and Canyon Creek Behavioral Health
Related Party Transaction [Line Items]
Fair market value of real estate assets sold										83,700,000
Relationship with Universal Health Realty Income Trust | Advisory Fee
Related Party Transaction [Line Items]
Net revenues		1,300,000	1,100,000	$ 2,500,000				$ 2,200,000
Premier, Inc. | Other (Income) Expense, Net
Related Party Transaction [Line Items]
Dividend		$ 450,000	$ 400,000			900,000	$ 800,000
Premier, Inc. | Group Purchasing Organization Agreement | Restricted Stock
Related Party Transaction [Line Items]
Shares vesting period					7 years
Shares vesting period start year					2014
Shares vesting period end year					2020
Market value of retained vested shares						$ 80,000,000				$ 92,000,000

Summary of Details of Hospitals

Summary of Details of Hospitals Leased from Trust (Detail) - USD ($)		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Property Subject to or Available for Operating Lease [Line Items]
Lease and rental expense		$ 31,773,000	$ 29,149,000	$ 63,811,000	$ 60,473,000
McAllen Medical Center
Property Subject to or Available for Operating Lease [Line Items]
Lease and rental expense				$ 5,485,000
End of Lease Term				2026-12
Renewal Term (years)	[1]			5 years
Wellington Regional Medical Center
Property Subject to or Available for Operating Lease [Line Items]
Lease and rental expense				$ 6,319,000
End of Lease Term				2026-12
Renewal Term (years)	[2]			5 years
Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services
Property Subject to or Available for Operating Lease [Line Items]
Lease and rental expense				$ 3,895,000
End of Lease Term				2033-12
Renewal Term (years)				35 years
Canyon Creek Behavioral Health
Property Subject to or Available for Operating Lease [Line Items]
Lease and rental expense				$ 1,670,000
End of Lease Term				2033-12
Renewal Term (years)				35 years
Clive Behavioral Health Hospital
Property Subject to or Available for Operating Lease [Line Items]
Lease and rental expense				$ 2,628,000
End of Lease Term				2040-12
Renewal Term (years)				50 years
[1]We have one 5-year renewal option at existing lease rates (through 2031).[2]We have one 5-year renewal options at fair market value lease rates (through 2031). Upon the December 31, 2021 expiration of the lease on Wellington Regional Medical Center, a wholly-owned subsidiary of ours exercised its fair market value renewal option and renewed the lease for a 5-year term scheduled to expire on December 31, 2026. Effective January 1, 2022, the annual fair market value lease rate for this hospital is $6.3 million (there is no longer a bonus rental component of the lease payment). Beginning on January 1, 2023, and thereafter on each January 1 st

Summary of Details of Hospita_2

Summary of Details of Hospitals Leased from Trust (Parenthetical) (Detail) $ in Millions	6 Months Ended
	Jun. 30, 2022 USD ($) RenewalOption
Maximum
Property Subject to or Available for Operating Lease [Line Items]
Real estate leases option to extend lease term	10 years
Minimum
Property Subject to or Available for Operating Lease [Line Items]
Real estate leases option to extend lease term	5 years
McAllen Medical Center
Property Subject to or Available for Operating Lease [Line Items]
Renewal options term at existing lease rates	5 years
McAllen Medical Center | Maximum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at existing lease rates expiration year	2031
Wellington Regional Medical Center
Property Subject to or Available for Operating Lease [Line Items]
Renewal options term at fair market lease rates	5 years
Real estate leases option to extend lease term	5 years
Lease expiration date	Dec. 31, 2026
Lease rent receivable | $	$ 6.3
Percentage of annual rental increase on cumulative and compound basis	2.50%
Wellington Regional Medical Center | Maximum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2031
Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services
Property Subject to or Available for Operating Lease [Line Items]
Renewal options term at fair market lease rates	5 years
Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services | Maximum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2068
Aiken Regional Medical Center/Aurora Pavilion Behavioral Health Services | Minimum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2034
Canyon Creek Behavioral Health
Property Subject to or Available for Operating Lease [Line Items]
Renewal options term at fair market lease rates	5 years
Canyon Creek Behavioral Health | Maximum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2068
Canyon Creek Behavioral Health | Minimum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2034
Clive Behavioral Health Hospital
Property Subject to or Available for Operating Lease [Line Items]
Renewal options term at fair market lease rates	10 years
Percentage of annual rental increase on cumulative and compound basis	2.75%
Operating leases additional renewal options term at fair market value lease rates	10 years
Number of lease renewal option exercised | RenewalOption	3
Clive Behavioral Health Hospital | Maximum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2070
Operating leases additional renewal options at fair market value lease rates expiration year	2090
Clive Behavioral Health Hospital | Minimum
Property Subject to or Available for Operating Lease [Line Items]
Renewal options at fair market value lease rates expiration year	2041
Operating leases additional renewal options at fair market value lease rates expiration year	2071

Other Noncurrent Liabilities _2

Other Noncurrent Liabilities and Redeemable/Noncontrolling Interests - Additional Information (Detail) $ in Millions	Jun. 30, 2022 USD ($) Facility
Minority Interest [Line Items]
Behavioral health care facilities with outside owners holding non-controlling minority interest | Facility	7
Non-controlling interest balances	$ 89
Redeemable non-controlling interest balances	$ 4
Outside Owners | Acute Care Facility | Washington, District of Columbia
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	20%
Outside Owners | Acute Care Facility | Texas
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	7%
Outside Owners | Acute Care Facility | Nevada
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	5%
Outside Owners | Behavioral Health Care Facility | Arizona
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	49%
Outside Owners | Behavioral Health Care Facility | Pennsylvania
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	20%
Outside Owners | Behavioral Health Care Facility | Ohio
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	30%
Outside Owners | Behavioral Health Care Facility | Washington
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	20%
Outside Owners | Behavioral Health Care Facility | Missouri
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	25%
Outside Owners | Behavioral Health Care Facility | Iowa
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	48%
Outside Owners | Behavioral Health Care Facility | Michigan
Minority Interest [Line Items]
Percentage of non-controlling, minority ownership interests held by outside owners	26%

Treasury - Additional Informati

Treasury - Additional Information (Detail) - USD ($)				1 Months Ended	3 Months Ended	6 Months Ended
	Sep. 13, 2021	Aug. 24, 2021	Sep. 28, 2020	Aug. 31, 2021	Mar. 31, 2022	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021	Apr. 30, 2021	Sep. 21, 2020	Oct. 23, 2018
Equity Class Of Treasury Stock [Line Items]
Rate adjustment to weighted average federal funds rate for credit facility borrowings					0.50%	0.50%
Rate adjustment to one month Eurodollar rate on credit facility borrowings					1%	1%
Accounts receivable securitization program credit facility, borrowing capacity						$ 450,000,000
Accounts receivable securitization program credit facility, available borrowing capacity									$ 20,000,000
Securitized extended maturity date						Jul. 22, 2022
Accounts receivable securitization program credit facility, amount outstanding						$ 0
Debt instrument carrying amount						4,700,000,000		$ 4,200,000,000
Fair value of debt						4,300,000,000		4,200,000,000
Cash flow hedges						0		0
Foreign Currency Forward Exchange Contracts
Equity Class Of Treasury Stock [Line Items]
Net cash (outflows) inflows						85,000,000	$ (21,000,000)
Debt
Equity Class Of Treasury Stock [Line Items]
Financial liabilities						82,000,000		$ 82,000,000
Tranche A Term Loan
Equity Class Of Treasury Stock [Line Items]
Line of credit facility, borrowing capacity						$ 700,000,000
Line of credit facility, maturity date						Aug. 24, 2026
Line of credit facility increased (decreased) amount				$ 150,000,000		$ 700,000,000
Line of credit facility amount outstanding					$ 1,700,000,000	2,368,000,000
Tranche A Term Loan | Quarterly Payment Beginning on December 31,2021 Through September 2023
Equity Class Of Treasury Stock [Line Items]
Scheduled principal payments per quarter						$ 15,000,000
Debt instrument payment, description						during the period of September, 2022 through September, 2023
Tranche A Term Loan | Quarterly Payment Beginning on December 31,2023 Through June 30, 2026
Equity Class Of Treasury Stock [Line Items]
Scheduled principal payments per quarter						$ 30,000,000
Debt instrument payment, description						during the period of December, 2023 through June, 2026
Revolving Credit Facility
Equity Class Of Treasury Stock [Line Items]
Line of credit facility, borrowing capacity		$ 1,200,000,000									$ 1,000,000,000
Line of credit facility, maturity date						Aug. 24, 2026
Line of credit facility increased (decreased) amount		$ 200,000,000
Line of credit facility amount outstanding						$ 140,000,000
Line of credit facility, available borrowing capacity						$ 1,056,000,000
Revolving Credit Facility | One Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Current applicable margins					1.375%
Revolving Credit Facility | ABR-based loans
Equity Class Of Treasury Stock [Line Items]
Current applicable margins					0.375%	0.375%
Revolving Credit Facility | One Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Current applicable margins						1.375%
Revolving Credit Facility | Letter of Credit
Equity Class Of Treasury Stock [Line Items]
Line of credit facility, borrowing capacity					$ 125,000,000	$ 125,000,000
Letters of credit, outstanding						$ 4,000,000
Revolving Credit Facility | Minimum | One Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio					0.25%
Revolving Credit Facility | Minimum | One Three Six Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio					1.25%
Revolving Credit Facility | Minimum | One Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio						0.25%
Revolving Credit Facility | Minimum | One Three Six Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio						1.25%
Revolving Credit Facility | Maximum | One Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio					0.625%
Revolving Credit Facility | Maximum | One Three Six Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio					1.625%
Revolving Credit Facility | Maximum | One Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio						0.625%
Revolving Credit Facility | Maximum | One Three Six Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio						1.625%
Tranche B Term Loan
Equity Class Of Treasury Stock [Line Items]
Line of credit facility amount outstanding						$ 488,000,000
New Senior Secured Notes
Equity Class Of Treasury Stock [Line Items]
Senior notes, issued						2,000,000,000
New Senior Secured Notes | 5.00% Senior Secured Notes due 2026
Equity Class Of Treasury Stock [Line Items]
Senior notes, interest rate	5%
Senior notes, redeemed	$ 400,000,000
Redemption price, percentage	102.50%
Senior notes, redemption price	$ 410,000,000
New Senior Secured Notes | 1.65% Senior Secured Notes due 2026
Equity Class Of Treasury Stock [Line Items]
Line of credit facility, maturity date		Sep. 01, 2026
Senior notes, issued		$ 700,000,000				$ 700,000,000
Senior notes, interest rate		1.65%				1.65%
New Senior Secured Notes | 2.65% Senior Secured Notes due 2032
Equity Class Of Treasury Stock [Line Items]
Line of credit facility, maturity date		Jan. 15, 2032
Senior notes, issued	$ 500,000,000	$ 500,000,000
Senior notes, interest rate	2.65%	2.65%
New Senior Secured Notes | 2.65% Senior Secured Notes due 2030
Equity Class Of Treasury Stock [Line Items]
Line of credit facility, maturity date						Oct. 15, 2030
Senior notes, issued										$ 800,000,000
Senior notes, interest rate										2.65%
New Senior Secured Notes | 4.75% Senior Secured Notes due 2022
Equity Class Of Treasury Stock [Line Items]
Senior notes, interest rate			4.75%
Senior notes, redeemed			$ 700,000,000
Redemption price, percentage			100%
New Senior Secured Notes | 5.00% Senior Secured Notes due 2026
Equity Class Of Treasury Stock [Line Items]
Line of credit facility, maturity date						Sep. 01, 2026
New Senior Secured Notes | Maximum
Equity Class Of Treasury Stock [Line Items]
Number of days to complete exchange offer						60 days
Term Loan A | One Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Current applicable margins					1.375%
Term Loan A | ABR-based loans
Equity Class Of Treasury Stock [Line Items]
Current applicable margins					0.375%	0.375%
Term Loan A | One Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Current applicable margins						1.375%
Term Loan A | Minimum | One Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio					0.25%
Term Loan A | Minimum | One Three Six Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio					1.25%
Term Loan A | Minimum | One Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio						0.25%
Term Loan A | Minimum | One Three Six Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio						1.25%
Term Loan A | Maximum | One Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio					0.625%
Term Loan A | Maximum | One Three Six Month LIBOR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio					1.625%
Term Loan A | Maximum | One Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio						0.625%
Term Loan A | Maximum | One Three Six Month SOFR Rate Plus Index Based Loans
Equity Class Of Treasury Stock [Line Items]
Consolidated Leverage Ratio						1.625%

Summary of Effects of Foreign C

Summary of Effects of Foreign Currency Foreign Exchange Contracts on Result of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Designated As Hedging Instrument | Net Investment Hedge | Foreign Currency Foreign Exchange Contracts
Derivative Instruments Gain Loss [Line Items]
Gain/(Loss) recognized in AOCI	$ 64,464	$ (9,917)	$ 81,576	$ (31,031)

Summary of Cash, Cash Equivalen

Summary of Cash, Cash Equivalents and Restricted Cash Reported In Condensed Consolidated Statements of Cash Flows (Detail) - USD ($) $ in Thousands		Jun. 30, 2022	Dec. 31, 2021	Jun. 30, 2021
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect [Abstract]
Cash and cash equivalents		$ 132,658	$ 115,301	$ 199,017
Restricted cash	[1]	$ 69,253	$ 63,633	$ 54,671
Restricted Cash, Statement of Financial Position [Extensible Enumeration]		us-gaap:OtherAssetsNoncurrent	us-gaap:OtherAssetsNoncurrent	us-gaap:OtherAssetsNoncurrent
Total cash, cash equivalents and restricted cash		$ 201,911	$ 178,934	$ 253,688
[1]Restricted cash is included in other assets on the accompanying consolidated balance sheet.

Summary of Assets and Liabiliti

Summary of Assets and Liabilities Recorded at Fair Value on Recurring Basis (Detail) - Recurring - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Assets:
Assets, fair value	$ 207,191	$ 221,235
Liabilities:
Liabilities, fair value	38,690	45,759
Money Market Mutual Funds | Other Assets
Assets:
Assets, fair value	85,037	79,900
Certificates of Deposit | Other Assets
Assets:
Assets, fair value	2,200	2,300
Equity Securities | Other Assets
Assets:
Assets, fair value	79,662	91,919
Deferred Compensation Assets | Other Assets
Assets:
Assets, fair value	38,690	45,759
Foreign Currency Foreign Exchange Contracts | Other Current Assets
Assets:
Assets, fair value	1,602	1,357
Deferred Compensation Liability | Other Noncurrent Liabilities
Liabilities:
Liabilities, fair value	38,690	45,759
Basis of Fair Value Measurement, Level 1
Assets:
Assets, fair value	203,389	217,578
Liabilities:
Liabilities, fair value	38,690	45,759
Basis of Fair Value Measurement, Level 1 | Money Market Mutual Funds | Other Assets
Assets:
Assets, fair value	85,037	79,900
Basis of Fair Value Measurement, Level 1 | Equity Securities | Other Assets
Assets:
Assets, fair value	79,662	91,919
Basis of Fair Value Measurement, Level 1 | Deferred Compensation Assets | Other Assets
Assets:
Assets, fair value	38,690	45,759
Basis of Fair Value Measurement, Level 1 | Deferred Compensation Liability | Other Noncurrent Liabilities
Liabilities:
Liabilities, fair value	38,690	45,759
Basis of Fair Value Measurement, Level 2
Assets:
Assets, fair value	3,802	3,657
Basis of Fair Value Measurement, Level 2 | Certificates of Deposit | Other Assets
Assets:
Assets, fair value	2,200	2,300
Basis of Fair Value Measurement, Level 2 | Foreign Currency Foreign Exchange Contracts | Other Current Assets
Assets:
Assets, fair value	$ 1,602	$ 1,357

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) £ in Millions	3 Months Ended		6 Months Ended			12 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2022 GBP (£)	Jun. 30, 2021 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Jun. 30, 2022 GBP (£)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jun. 30, 2020 USD ($)	Jun. 01, 2020 USD ($)	Dec. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)
Commitments and Contingencies Disclosure [Line Items]
Self-insured for professional and general liability, current	$ 74,000,000		$ 74,000,000									$ 74,000,000
Compensation liability claims	121,000,000		121,000,000									115,000,000
Compensation and related benefits	$ 55,000,000		$ 55,000,000									55,000,000
GW Hospital
Commitments and Contingencies Disclosure [Line Items]
Purchase of minority ownership interest percentage	20%
Department of Human Services
Commitments and Contingencies Disclosure [Line Items]
Repayment of legal settlement amount on demand						$ 4,000,000	$ 4,000,000	$ 4,000,000	$ 4,000,000	$ 4,000,000
Amount claimed from over payments of legal settlements						7,000,000	8,000,000	7,000,000	$ 4,000,000
Amount claimed from over payments of legal settlements due to change in calculations						3,000,000	2,000,000	$ 2,000,000
Wind Storms
Commitments and Contingencies Disclosure [Line Items]
Maximum insurance deductible															$ 2,500,000
Cygnet Health Care Limited
Commitments and Contingencies Disclosure [Line Items]
Property insurance | £				£ 1,500
Maximum | Wind Storms
Commitments and Contingencies Disclosure [Line Items]
Commercial property insurance policies covering catastrophic losses															$ 1,000,000,000
Percentage of insurance deductible	5%		5%								5%
Maximum | Earthquake | CALIFORNIA
Commitments and Contingencies Disclosure [Line Items]
Commercial property insurance policies covering catastrophic losses	$ 150,000,000		$ 150,000,000
Maximum | Earthquake | Faulty Zones of UNITED STATES
Commitments and Contingencies Disclosure [Line Items]
Commercial property insurance policies covering catastrophic losses	100,000,000		100,000,000
Maximum | Earthquake | PUERTO RICO
Commitments and Contingencies Disclosure [Line Items]
Commercial property insurance policies covering catastrophic losses	40,000,000		40,000,000
Maximum | Earthquake | OTHER STATES
Commitments and Contingencies Disclosure [Line Items]
Commercial property insurance policies covering catastrophic losses	250,000,000		250,000,000
Maximum | Flood
Commitments and Contingencies Disclosure [Line Items]
Commercial property insurance policies covering catastrophic losses	100,000,000		100,000,000
Maximum | Flood | PUERTO RICO
Commitments and Contingencies Disclosure [Line Items]
Commercial property insurance policies covering catastrophic losses	1,000,000		1,000,000
Maximum | Flood | Texas
Commitments and Contingencies Disclosure [Line Items]
Commercial property insurance policies covering catastrophic losses	$ 10,000,000		$ 10,000,000
Minimum | Wind Storms
Commitments and Contingencies Disclosure [Line Items]
Percentage of insurance deductible	3%		3%								3%
General And Professional Liability Insurance Policies
Commitments and Contingencies Disclosure [Line Items]
Self-insured for professional and general liability	$ 16,000,000	$ 36,000,000	$ 16,000,000		$ 36,000,000
General and Professional Liability
Commitments and Contingencies Disclosure [Line Items]
Self-insured for professional and general liability	382,000,000		382,000,000									349,000,000
Subsidiaries | Professional Liability
Commitments and Contingencies Disclosure [Line Items]
Purchased several excess policies through commercial insurance carriers per occurrence														$ 2,500,000
Purchased several excess policies through commercial insurance carriers per occurrence excess claim amount														10,000,000
Subsidiaries | Professional Liability | Cygnet Health Care Limited
Commitments and Contingencies Disclosure [Line Items]
Self-insured for professional and general liability | £											£ 16
Subsidiaries | Professional Liability | Maximum
Commitments and Contingencies Disclosure [Line Items]
Self-insured for professional and general liability	20,000,000		20,000,000									20,000,000		10,000,000		$ 5,000,000	$ 5,000,000	$ 5,000,000	$ 10,000,000
Subsidiaries | General Liability | Cygnet Health Care Limited
Commitments and Contingencies Disclosure [Line Items]
Self-insured for professional and general liability | £											£ 25
Subsidiaries | General Liability | Maximum
Commitments and Contingencies Disclosure [Line Items]
Self-insured for professional and general liability	3,000,000		3,000,000									3,000,000		$ 3,000,000		3,000,000	3,000,000	3,000,000	3,000,000
Subsidiaries | General And Professional Liability Insurance Policies | Maximum
Commitments and Contingencies Disclosure [Line Items]
Purchased several excess policies through commercial insurance carriers per occurrence	$ 162,500,000		$ 162,500,000			$ 250,000,000	$ 250,000,000					$ 155,000,000	$ 250,000,000			$ 250,000,000	$ 250,000,000	$ 250,000,000	$ 250,000,000

Segment Reporting (Detail)

Segment Reporting (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Gross inpatient revenues		$ 12,268,284	$ 11,190,111	$ 24,943,989	$ 22,782,860
Gross outpatient revenues		6,474,528	5,624,216	12,507,180	10,451,700
Total net revenues		3,323,407	3,197,880	6,616,363	6,210,867
Income/(loss) before allocation of corporate overhead and income taxes		209,730	426,798	409,713	699,675
Allocation of corporate overhead		0	0	0	0
Income before income taxes		209,730	426,798	409,713	699,675
Total assets		13,296,103	12,812,635	13,296,103	12,812,635	$ 13,093,543
Acute Care Hospital Services
Segment Reporting Information [Line Items]
Gross inpatient revenues		9,706,731	8,662,335	19,945,962	17,781,519
Gross outpatient revenues		6,206,039	5,357,888	11,981,578	9,938,608
Total net revenues		1,875,516	1,754,431	3,787,832	3,448,973
Income/(loss) before allocation of corporate overhead and income taxes		95,059	218,663	243,739	391,781
Allocation of corporate overhead		(63,213)	(58,227)	(125,497)	(116,334)
Income before income taxes		31,846	160,436	118,242	275,447
Total assets		5,785,470	5,162,252	5,785,470	5,162,252
Behavioral Health Services
Segment Reporting Information [Line Items]
Gross inpatient revenues	[1]	2,561,553	2,527,776	4,998,027	5,001,341
Gross outpatient revenues	[1]	268,489	266,328	525,602	513,092
Total net revenues	[1]	1,433,920	1,431,497	2,800,387	2,746,834
Income/(loss) before allocation of corporate overhead and income taxes	[1]	249,958	324,577	455,746	555,902
Allocation of corporate overhead	[1]	(45,063)	(43,099)	(90,064)	(86,049)
Income before income taxes	[1]	204,895	281,478	365,682	469,853
Total assets	[1]	7,251,966	7,159,426	7,251,966	7,159,426
Other
Segment Reporting Information [Line Items]
Gross inpatient revenues			0		0
Gross outpatient revenues			0		0
Total net revenues		13,971	11,952	28,144	15,060
Income/(loss) before allocation of corporate overhead and income taxes		(135,287)	(116,442)	(289,772)	(248,008)
Allocation of corporate overhead		108,276	101,326	215,561	202,383
Income before income taxes		(27,011)	(15,116)	(74,211)	(45,625)
Total assets		$ 258,667	$ 490,957	$ 258,667	$ 490,957
[1] Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $173 million and $172 million for the three-month periods ended June 30, 2022 and 2021, respectively, and approximately $349 million and $337 million for the six-month periods ended June 30, 2022 and 2021, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.220 billion and $1.369 billion as of June 30, 2022 and 2021, respectively.

Segment Reporting (Parenthetica

Segment Reporting (Parenthetical) (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Segment Reporting Information [Line Items]
Net revenues		$ 3,323,407	$ 3,197,880	$ 6,616,363	$ 6,210,867
Total assets		13,296,103	12,812,635	13,296,103	12,812,635	$ 13,093,543
Behavioral Health Services
Segment Reporting Information [Line Items]
Net revenues	[1]	1,433,920	1,431,497	2,800,387	2,746,834
Total assets	[1]	7,251,966	7,159,426	7,251,966	7,159,426
Behavioral Health Services | Located in U.K.
Segment Reporting Information [Line Items]
Net revenues		173,000	172,000	349,000	337,000
Total assets		$ 1,220,000	$ 1,369,000	$ 1,220,000	$ 1,369,000
[1] Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $173 million and $172 million for the three-month periods ended June 30, 2022 and 2021, respectively, and approximately $349 million and $337 million for the six-month periods ended June 30, 2022 and 2021, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.220 billion and $1.369 billion as of June 30, 2022 and 2021, respectively.

Computation of Basic and Dilute

Computation of Basic and Diluted Earnings Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Basic and Diluted:
Net income attributable to UHS	$ 164,062	$ 325,024	$ 317,975	$ 534,115
Less: Net income attributable to unvested restricted share grants	(164)	(661)	(413)	(1,213)
Net income attributable to UHS – basic and diluted	$ 163,898	$ 324,363	$ 317,562	$ 532,902
Weighted average number of common shares - basic	73,682	84,224	74,356	84,503
Net effect of dilutive stock options and grants based on the treasury stock method	753	1,400	882	1,207
Weighted average number of common shares and equivalents - diluted	74,435	85,624	75,238	85,710
Earnings per basic share attributable to UHS:	$ 2.22	$ 3.85	$ 4.27	$ 6.31
Earnings per diluted share attributable to UHS:	$ 2.20	$ 3.79	$ 4.22	$ 6.22

Earnings Per Share Data ("EPS_3

Earnings Per Share Data ("EPS") and Stock Based Compensation - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Anti-dilutive weighted average stock options excluded from computation of earnings per share	5,600,000	4,200,000	5,600,000	4,400,000
Stock options granted during period			1,821,573
Weighted-average grant date fair value, per option			$ 45.67
Compensation cost recognized			$ 41,640	$ 37,031
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized, pre-tax charge	$ 17,600	$ 15,500	32,800	30,200
Restricted Stock Awards, Restricted Stock Units and Performance Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation cost recognized, pre-tax charge	4,700	$ 3,200	$ 8,100	$ 6,100
Unrecognized compensation cost vesting period			3 years
Unvested Stock option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to unvested options and restricted stock	$ 191,700		$ 191,700
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares and restricted units granted during period			248,684
Weighted-average grant date fair value, per share			$ 142.97
Performance Based Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted shares and restricted units granted during period			73,782

Dispositions and Acquisitions -

Dispositions and Acquisitions - Additional Information (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Business Combinations [Abstract]
Acquisition, cash paid	$ 12,000,000	$ 0
Aggregate cash proceeds from divestiture of businesses	$ 10,000,000	$ 21,000,000

Dividends - Additional Informat

Dividends - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Dividends [Abstract]
Dividends declared and paid	$ 14.7	$ 16.8	$ 29.4	$ 33.8
Dividends declared and paid, per share	$ 0.20	$ 0.20	$ 40	$ 40

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Jan. 31, 2022
Income Taxes [Line Items]
Effective income tax rate	24.30%	23.80%	24.40%	23.60%
Provisional deferred tax - GILTI			$ 0	$ 0
Unrecognized tax benefits					$ 2,000,000
Impact of unrecognized tax benefits if recognized					$ 2,000,000
Period of expiration of the statute of limitations for certain jurisdictions			within the next twelve months
Jurisdictions statutes of limitations expiration period			12 months
Maximum
Income Taxes [Line Items]
Accrued interest and penalties	$ 1,000,000		$ 1,000,000
Foreign and U.S. state and local jurisdictions have statutes of limitations, in years			4 years
Minimum
Income Taxes [Line Items]
Foreign and U.S. state and local jurisdictions have statutes of limitations, in years			3 years

Schedule of Disaggregates Reven

Schedule of Disaggregates Revenue by Major Source (Detail) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation Of Revenue [Line Items]
Net revenues		$ 3,323,407	$ 3,197,880	$ 6,616,363	$ 6,210,867
Percentage of Net Revenue		100%	100%	100%	100%
Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 401,516	$ 400,938	$ 818,137	$ 824,943
Percentage of Net Revenue		12%	13%	12%	13%
Managed Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 377,462	$ 335,925	$ 773,560	$ 669,027
Percentage of Net Revenue		11%	11%	12%	11%
Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 368,009	$ 397,229	$ 699,248	$ 662,010
Percentage of Net Revenue		11%	12%	11%	11%
Managed Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 526,263	$ 495,463	$ 1,032,065	$ 965,719
Percentage of Net Revenue		16%	15%	16%	16%
Managed Care (HMO and PPOs)
Disaggregation Of Revenue [Line Items]
Net revenues		$ 1,003,486	$ 960,952	$ 2,007,586	$ 1,908,506
Percentage of Net Revenue		30%	30%	30%	31%
UK Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 173,231	$ 172,220	$ 349,323	$ 336,886
Percentage of Net Revenue		5%	5%	5%	5%
Other Patient Revenue and Adjustments, Net
Disaggregation Of Revenue [Line Items]
Net revenues		$ 200,118	$ 213,101	$ 412,961	$ 427,634
Percentage of Net Revenue		6%	7%	6%	7%
Other Non-patient Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 273,322	$ 222,052	$ 523,483	$ 416,142
Percentage of Net Revenue		8%	7%	8%	7%
Acute Care Hospital Services
Disaggregation Of Revenue [Line Items]
Net revenues		$ 1,875,516	$ 1,754,431	$ 3,787,832	$ 3,448,973
Percentage of Net Revenue		100%	100%	100%	100%
Acute Care Hospital Services | Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 318,166	$ 308,211	$ 655,275	$ 643,724
Percentage of Net Revenue		17%	18%	17%	19%
Acute Care Hospital Services | Managed Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 306,585	$ 274,393	$ 638,833	$ 549,953
Percentage of Net Revenue		16%	16%	17%	16%
Acute Care Hospital Services | Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 184,098	$ 169,705	$ 339,934	$ 281,346
Percentage of Net Revenue		10%	10%	9%	8%
Acute Care Hospital Services | Managed Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 162,092	$ 161,261	$ 333,729	$ 296,759
Percentage of Net Revenue		9%	9%	9%	9%
Acute Care Hospital Services | Managed Care (HMO and PPOs)
Disaggregation Of Revenue [Line Items]
Net revenues		$ 627,475	$ 588,806	$ 1,266,370	$ 1,187,616
Percentage of Net Revenue		33%	34%	33%	34%
Acute Care Hospital Services | UK Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 0	$ 0	$ 0	$ 0
Percentage of Net Revenue		0%	0%	0%	0%
Acute Care Hospital Services | Other Patient Revenue and Adjustments, Net
Disaggregation Of Revenue [Line Items]
Net revenues		$ 74,123	$ 84,157	$ 166,233	$ 178,407
Percentage of Net Revenue		4%	5%	4%	5%
Acute Care Hospital Services | Other Non-patient Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 202,977	$ 167,898	$ 387,458	$ 311,168
Percentage of Net Revenue		11%	10%	10%	9%
Behavioral Health Services
Disaggregation Of Revenue [Line Items]
Net revenues	[1]	$ 1,433,920	$ 1,431,497	$ 2,800,387	$ 2,746,834
Percentage of Net Revenue		100%	100%	100%	100%
Behavioral Health Services | Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 83,350	$ 92,727	$ 162,862	$ 181,219
Percentage of Net Revenue		6%	6%	6%	7%
Behavioral Health Services | Managed Medicare
Disaggregation Of Revenue [Line Items]
Net revenues		$ 70,877	$ 61,532	$ 134,727	$ 119,074
Percentage of Net Revenue		5%	4%	5%	4%
Behavioral Health Services | Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 183,911	$ 227,524	$ 359,314	$ 380,664
Percentage of Net Revenue		13%	16%	13%	14%
Behavioral Health Services | Managed Medicaid
Disaggregation Of Revenue [Line Items]
Net revenues		$ 364,171	$ 334,202	$ 698,336	$ 668,960
Percentage of Net Revenue		25%	23%	25%	24%
Behavioral Health Services | Managed Care (HMO and PPOs)
Disaggregation Of Revenue [Line Items]
Net revenues		$ 376,011	$ 372,146	$ 741,216	$ 720,890
Percentage of Net Revenue		26%	26%	26%	26%
Behavioral Health Services | UK Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 173,231	$ 172,220	$ 349,323	$ 336,886
Percentage of Net Revenue		12%	12%	12%	12%
Behavioral Health Services | Other Patient Revenue and Adjustments, Net
Disaggregation Of Revenue [Line Items]
Net revenues		$ 125,995	$ 128,944	$ 246,728	$ 249,227
Percentage of Net Revenue		9%	9%	9%	9%
Behavioral Health Services | Other Non-patient Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 56,374	$ 42,202	$ 107,881	$ 89,914
Percentage of Net Revenue		4%	3%	4%	3%
Other
Disaggregation Of Revenue [Line Items]
Net revenues		$ 13,971	$ 11,952	$ 28,144	$ 15,060
Other | Other Non-patient Revenue
Disaggregation Of Revenue [Line Items]
Net revenues		$ 13,971	$ 11,952	$ 28,144	$ 15,060
[1] Includes net revenues generated from our behavioral health care facilities located in the U.K. amounting to approximately $173 million and $172 million for the three-month periods ended June 30, 2022 and 2021, respectively, and approximately $349 million and $337 million for the six-month periods ended June 30, 2022 and 2021, respectively. Total assets at our U.K. behavioral health care facilities were approximately $1.220 billion and $1.369 billion as of June 30, 2022 and 2021, respectively.

Lease Accounting - Additional I

Lease Accounting - Additional Information (Detail)	6 Months Ended
	Jun. 30, 2022 Hospital
Lessee Lease Description [Line Items]
Lessee, operating lease, existence of option to extend [true false]	true
Number of hospital facilities	5
Two Hospital Facilities
Lessee Lease Description [Line Items]
Lease expiration term	2026
Another Two Hospital Facilities
Lessee Lease Description [Line Items]
Lease expiration term	2033
One Hospital Facility
Lessee Lease Description [Line Items]
Lease expiration term	2040
Minimum
Lessee Lease Description [Line Items]
Initial term of real estate lease	5 years
Real estate leases option to extend lease term	5 years
Maximum
Lessee Lease Description [Line Items]
Initial term of real estate lease	10 years
Real estate leases option to extend lease term	10 years

Supplemental Cash Flow Informat

Supplemental Cash Flow Information Related to Leases (Detail) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 61,964	$ 59,818
Operating cash flows from finance leases	2,000	2,352
Financing cash flows from finance leases	1,798	1,589
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	27,930	12,322
Finance leases	$ 1,066	$ 7,690